| (Mark One) |
|------------|
|       |   |
| ý     | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|       |   |
|  ̈     | For the fiscal year ended December 31, 2009 |
|       |   |
|       | OR |
|       |   |
|       | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|       |   |
|       | For the transition period from            __________to        __________                        |

| The Netherlands                                                | Not Applicable                       |
|----------------------------------------------------------------|--------------------------------------|
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
| Herengracht 424                                                |                                 |
| 1017 BZ Amsterdam                                              |                                 |
| The Netherlands                                                | Not Applicable                       |
| (Address of principal executive offices)                       | (Zip Code)                           |
|                                                           |                                 |

| Title of each class                         | Name of exchange on which registered |
|---------------------------------------------|--------------------------------------|
| Common Shares, EUR 0.04 Par Value Per Share | New York Stock Exchange              |

| Large accelerated filer  ý | Accelerated filer   ̈ | Non-accelerated filer   ̈       | Smaller reporting company   ̈ |
|-------------------------------------------|-------------------------------------|-----------------------------------------------|---------------------------------------------|
|                                      |                                | (Do not check if a smaller reporting company) |

----

TABLE OF CONTENTS

|     |                                                                                                         | Page   |
|----------|--------------------------------------------------------------------------------------------------------------|--------|
|     |                                                                                                         |   |
| PART I   |
| Item 1.  | Business                                                                                                     | 1      |
| Item 1A. | Risk Factors                                                                                                 | 7      |
| Item 1B. | Unresolved Staff Comments                                                                                    | 11     |
| Item 2.  | Properties                                                                                                   | 11     |
| Item 3.  | Legal Proceedings                                                                                            | 11     |
| Item 4.  | Submission of Matters to a Vote of Security Holders                                                          | 11     |
| PART II  |
| Item 5.  | Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | 12     |
| Item 6.  | Selected Financial Data                                                                                      | 14     |
| Item 7.  | Management's Discussion and Analysis of Financial Condition and Results of Operation                         | 15     |
| Item 7A. | Quantitative and Qualitative Disclosures about Market Risk                                                   | 28     |
| Item 8.  | Financial Statements and Supplementary Data                                                                  | 29     |
| Item 9.  | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure                         | 29     |
| Item 9A. | Controls and Procedures                                                                                      | 29     |
| Item 9B. | Other Information                                                                                            | 30     |
| PART III |
| Item 10. | Directors, Executive Officers and Corporate Governance                                                       | 30     |
| Item 11. | Executive Compensation                                                                                       | 30     |
| Item 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters               | 30     |
| Item 13. | Certain Relationships and Related Transactions and Director Independence                                     | 30     |
| Item 14. | Principal Accountant Fees and Services                                                                       | 30     |
| PART IV  |
| Item 15. | Exhibits, Financial Statement Schedules                                                                      | 31     |

----

ITEM 1. BUSINESS

Return to table of contents

----

| -      | Reservoir Description: Encompasses the characterization of petroleum reservoir rock, fluid and gas samples. We provide analytical and field services to characterize properties of crude oil and petroleum products to the oil and gas industry.                                                                            |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                        |
| -      | Production Enhancement: Includes products and services relating to reservoir well completions, perforations, stimulations and production. We provide integrated services to evaluate the effectiveness of well completions and to develop solutions aimed at increasing the effectiveness ofenhanced oil recovery projects. |
|   |                                                                                                                                                                                                                                                                                                                        |
| -      | Reservoir Management: Combines and integrates information from reservoir description and production enhancement services to increase production and improve recovery of oil and gas from our clients' reservoirs.                                                                                                           |

Return to table of contents

----

Return to table of contents

----

Return to table of contents

----

Return to table of contents

----

Return to table of contents

----

ITEM 1A.  RISK FACTORS

| -      | general and economic business conditions;                                                                      |
|--------|----------------------------------------------------------------------------------------------------------------|
|   |                                                                                                           |
| -      | market prices of oil and gas and expectations about future prices;                                             |
|   |                                                                                                           |
| -      | cost of producing oil and natural gas;                                                                         |
|   |                                                                                                           |
| -      | the level of drilling and production activity;                                                                 |
|   |                                                                                                           |
| -      | mergers, consolidations and downsizing among our clients;                                                      |
|   |                                                                                                           |
| -      | coordination by OPEC;                                                                                          |
|   |                                                                                                           |
| -      | the impact of commodity prices on the expenditure levels of our clients;                                       |
|   |                                                                                                           |
| -      | financial condition of our client base and their ability to fund capital expenditures;                         |
|   |                                                                                                           |
| -      | the physical effects of climatic change, including adverse weather conditions;                                 |
|   |                                                                                                           |
| -      | civil unrest in oil producing countries;                                                                       |
|   |                                                                                                           |
| -      | level of consumption of oil, gas and petrochemicals by consumers;                                              |
|   |                                                                                                           |
| -      | the adoption of legal requirements relating to climate change that lower the demand for petroleum-based fuels; |
|   |                                                                                                           |
| -      | changes in existing laws or regulations;                                                                       |
|   |                                                                                                           |
| -      | the business opportunities (or lack thereof) that may be presented to and pursued by us; and                   |
|   |                                                                                                           |
| -      | availability of services and materials for our clients to grow their capital expenditures.                     |

Return to table of contents

----

| -      | global economic conditions;                                                                                                                                                               |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                      |
| -      | political actions and requirements of national governments including trade restrictions, embargoes, seizure, detention, nationalization and expropriations of assets;                     |
|   |                                                                                                                                                                                      |
| -      | interpretation of tax statutes and requirements of taxing authorities worldwide, routine examination by taxing authorities and assessment of additional taxes, penalties and/or interest; |
|   |                                                                                                                                                                                      |
| -      | civil unrest;                                                                                                                                                                             |
|   |                                                                                                                                                                                      |
| -      | acts of terrorism;                                                                                                                                                                        |
|   |                                                                                                                                                                                      |
| -      | fluctuations and changes in currency exchange rates;                                                                                                                                      |
|   |                                                                                                                                                                                      |
| -      | the impact of inflation;                                                                                                                                                                  |
|   |                                                                                                                                                                                      |
| -      | difficulty in repatriating foreign currency received in excess of the local currency requirements; and                                                                                    |
|   |                                                                                                                                                                                      |
| -      | current conditions in oil producing countries such as Venezuela, Nigeria, Iran and Iraq considering their potential impact on the world markets.                                          |

Return to table of contents

----

| -      | increased financial leverage;                                                 |
|--------|-------------------------------------------------------------------------------|
|   |                                                                          |
| -      | ability to obtain additional financing;                                       |
|   |                                                                          |
| -      | increased interest expense; and                                               |
|   |                                                                          |
| -      | difficulties involved in combining disparate company cultures and facilities. |

Return to table of contents

----

Return to table of contents

----

ITEM 1B

ITEM 2.

ITEM 3

ITEM 4.

Return to table of contents

----

ITEM 5

|           |   | High   |   |   | Low    |   |
|----------------|--------|--------|--------|--------|--------|--------|
| 2009           |   |   |   |   |   |   |
| First Quarter  |   | $      | 77.62  |   |   | $      | 60.49 |   |
| Second Quarter |   |   | 98.93  |   |   |   | 71.28 |   |
| Third Quarter  |   |   | 104.95 |   |   |   | 78.10 |   |
| Fourth Quarter |   |   | 119.34 |   |   |   | 98.58 |   |
| 2008           |   |   |   |   |   |   |   |   |
| First Quarter  |   | $      | 129.91 |   |   | $      | 102.08 |   |
| Second Quarter |   |   | 146.47 |   |   |   | 117.48 |   |
| Third Quarter  |   |   | 144.21 |   |   |   | 91.76 |   |
| Fourth Quarter |   |   | 99.40  |   |   |   | 48.52 |   |

Return to table of contents

----

| Period                  |   | Total Number Of Shares Purchased |   |   | Average Price Paid Per Share |   |   | Total Number Of Shares Purchased As Part Of A Publicly Announced Program |   |   | Maximum Number Of Shares That May Be Purchased Under The Program (3) |   |
|-------------------------|--------|----------------------------------|--------|--------|------------------------------|--------|--------|--------------------------------------------------------------------------|--------|--------|----------------------------------------------------------------------|--------|
| October 1-31, 2009      |   |                             | 0      |   |                         |   | 0      |                                                                     |   |   | 0                                                                    |   |   |   | 3,994,265 |   |
| November 1-30,2009 (1)  |   |                             | 114    |   |                         | $      | 106.27 |                                                                     |   |   | 114                                                                  |   |   |   | 3,994,501 |   |
| December 1-31, 2009 (2) |   |                             | 2,144  |   |                         | $      | 108.22 |                                                                     |   |   | 2,144                                                                |   |   |   | 3,999,857 |   |
| Total                   |   |                             | 2,258  |   |                         | $      | 108.12 |                                                                     |   |   | 2,258                                                                |   |   |   | 3,999,857 |   |

| (1)   | 114 shares valued at $12 thousand, or $106.27 per share, surrendered to us by participants in a stock-based compensation plan to settle any personal tax liabilities which may result from the award. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2)   | 2,144 shares valued at $0.2 million, or $108.22 per share, surrendered to us by participants in a stock-based compensation plan to settle any personal tax liabilities which may result from the award. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (3)   | During the quarter 8,350 shares were distributed from the share repurchase program relating to stock-based awards and stock options. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------|

Return to table of contents

----

ITEM 6.

|                                                                      |   | Year Ended December 31,                         |    |
|---------------------------------------------------------------------------|--------|-------------------------------------------------|---------|
|                                                                      |   | 2009                                            |    |   | 2008 (3) |   |   | 2007 (3) |   |   | 2006 (3) |   |   | 2005 |   |
|                                                                      |   | (in thousands, except per share and other data) |    |
|                                                                      |   |                                            |    |   |   |   |   |   |   |   |   |   |   |   |   |
| Financial Statement Data:                                                 |   |                                            |    |   |   |   |   |   |   |   |   |   |   |   |   |
| Revenues                                                                  |   | $                                               | 695,539 |   |   | $ | 780,836 |   |   | $ | 670,540 |   |   | $ | 575,689 |   |   | $ | 483,467 |   |
| Income from continuing operations attributable to Core Laboratories N.V.  |   |                                            | 113,604 |   |   |   | 131,166 |   |   |   | 111,212 |   |   |   | 81,045 |   |   |   | 31,717 |   |
| Net income attributable to Core Laboratories N.V.                         |   |                                            | 113,604 |   |   |   | 131,166 |   |   |   | 111,212 |   |   |   | 81,045 |   |   |   | 31,211 |   |
| Working capital                                                           |   |                                            | 284,129 |   |   |   | 139,955 |   |   |   | 116,276 |   |   |   | 130,249 |   |   |   | 83,689 |   |
| Total assets                                                              |   |                                            | 658,166 |   |   |   | 521,535 |   |   |   | 476,754 |   |   |   | 467,244 |   |   |   | 394,601 |   |
| Long-term debt and capital lease obligations,                             |   |                                            |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|    including current maturities                            |   |                                            | 209,112 |   |   |   | 194,568 |   |   |   | 230,594 |   |   |   | 214,503 |   |   |   | 88,648 |   |
| Total equity                                                              |   |                                            | 281,758 |   |   |   | 188,285 |   |   |   | 108,026 |   |   |   | 127,572 |   |   |   | 214,257 |   |
| Earnings Per Share Information:                                           |   |                                            |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Income from continuing operations attributable to Core Laboratories N.V.: |   |                                            |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|    Basic                                                   |   | $                                               | 4.95    |   |   | $ | 5.70 |   |   | $ | 4.72 |   |   | $ | 3.22 |   |   | $ | 1.22 |   |
|    Diluted                                                 |   | $                                               | 4.87    |   |   | $ | 5.48 |   |   | $ | 4.56 |   |   | $ | 3.01 |   |   | $ | 1.13 |   |
| Net income attributable to Core Laboratories N.V.:                        |   |                                            |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|    Basic                                                   |   | $                                               | 4.95    |   |   | $ | 5.70 |   |   | $ | 4.72 |   |   | $ | 3.22 |   |   | $ | 1.20 |   |
|    Diluted                                                 |   | $                                               | 4.87    |   |   | $ | 5.48 |   |   | $ | 4.56 |   |   | $ | 3.01 |   |   | $ | 1.11 |   |
| Weighted average common shares outstanding:                               |   |                                            |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|    Basic                                                   |   |                                            | 22,969  |   |   |   | 23,008 |   |   |   | 23,537 |   |   |   | 25,157 |   |   |   | 26,038 |   |
|    Diluted                                                 |   |                                            | 23,328  |   |   |   | 23,944 |   |   |   | 24,408 |   |   |   | 26,888 |   |   |   | 28,008 |   |
| Cash dividends declared per share                                         |   | $                                               | 1.15    |   |   | $ | 1.20 |   |   | $ | - |   |   | $ | - |   |   | $ | - |   |
| Other Data:                                                               |   |                                            |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Current ratio (1)                                                         |   | 3.7:1                                           |    |   | 2.5:1 |   |   | 2.2:1 |   |   | 2.5:1 |   |   | 2.2:1 |   |
| Debt to capitalization ratio (2)                                          |   |                                            | 34      | % |   |   | 52 | % |   |   | 69 | % |   |   | 62 | % |   |   | 28 | % |

| (1) | Current ratio is calculated as follows: current assets divided by current liabilities. |
|-----|----------------------------------------------------------------------------------------|

| (2) | Debt to capitalization ratio is calculated as follows: debt divided by the sum of cash, debt and equity. |
|-----|----------------------------------------------------------------------------------------------------------|

| (3) |   Results have been revised upon adoption of FASB Accounting Standards Codification 470-20.  See Note 8 Debt and Capital Lease Obligations for more information. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Return to table of contents

----

ITEM 7

| -      | Reservoir Description:  Encompasses the characterization of petroleum reservoir rock, fluid and gas samples.  We provide analytical and field services to characterize properties of crude oil and petroleum products to the oil and gas industry.                                                                            |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                              |
| -      | Production Enhancement:  Includes products and services relating to reservoir well completions, perforations, stimulations and production.  We provide integrated services to evaluate the effectiveness of well completions and to developsolutions aimed at increasing the effectiveness of enhanced oil recovery projects. |
|   |                                                                                                                                                                                                                                                                                                                                              |
| -      | Reservoir Management:  Combines and integrates information from reservoir description and production enhancement services to increase production and improve recovery of oil and gas from our clients' reservoirs.                                                                                                                      |

|                                                                                                                                                                                                        |   |   |   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|--------|
|                                                                                                                                                                                                        |   | 2009   |   |   | 2008 |   |   | 2007 |   |
|                                                                                                                                                                                                        |   |   |   |   |   |   |   |   |   |
| Worldwide Average Rig Count (1)                                                                                                                                                                             |   |   | 2,304  |   |   |   | 3,336 |   |   |   | 3,116 |   |
| U.S. Average Rig Count (1)                                                                                                                                                                                  |   |   | 1,086  |   |   |   | 1,878 |   |   |   | 1,768 |   |
| Average Crude Oil Price per Barrel (2)                                                                                                                                                                      |   | $      | 61.95  |   |   | $ | 99.67 |   |   | $ | 72.34 |   |
| Average Natural Gas Spot Price per MMBtu (3)                                                                                                                                                                |   | $      | 3.94   |   |   | $ | 8.89 |   |   | $ | 6.96 |   |
|                                                                                                                                                                                                        |   |   |   |   |   |   |   |   |   |   |   |   |
| (1) Twelve month average rig count as reported by Baker Hughes Incorporated - World-wide Rig Count .                                                                                                        |   |
| (2) Average daily West Texas Intermediate crude spot price.                                                                                                                                                 |   |
| (3) Obtained from U.S. Department of Energy Natural Gas Weekly Update daily average of the Henry Hub spot price for the years ended December 31, 2009, 2008, and 2007 per the New York Mercantile Exchange. |   |

Return to table of contents

----

Return to table of contents

----

Return to table of contents

----

Return to table of contents

----

| Account                                     |   | Nature of Estimates Required                                                                                                                                                                                                                                                                                                                                                                                                                                                     |   | Assumptions Used                                                                                                                                                                                                                                                                                        |
|---------------------------------------------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Allowance for doubtful accounts             |   | We evaluate whether client receivables are collectible.                                                                                                                                                                                                                                                                                                                                                                                                                          |   | See "Allowance for Doubtful Accounts."                                                                                                                                                                                                                                                                  |
| Inventory reserves                          |   | We forecast client demand, considering changes in technology which could result in obsolescence.                                                                                                                                                                                                                                                                                                                                                                                 |   | See "Inventory Valuation Allowances."                                                                                                                                                                                                                                                                   |
| Depreciation and amortization               |   | We estimate the useful lives and salvage values of our assets.                                                                                                                                                                                                                                                                                                                                                                                                                   |   | Useful lives assigned reflect our best estimate based on historical data of the respective asset's useful life and salvage value. These assets could become impaired if our operating plans or business environment changes.                                                                            |
| Pensions and other postretirement benefits  |   | We utilize an actuary to assist in determining the value of the projected benefit obligation under a Dutch pension plan.  This valuation requires various estimates and assumptions concerning mortality, future pay increases and discount rate used to value our obligations.  In addition, we recognize net periodic benefit costbased upon these estimates.                                                                                              |   | The actuarial assumptions used are based upon professional judgment and historical experience, including trends in mortality rates, and credit market rates (discount rate).                                                                                                                            |
| Stock-based compensation                    |   | We evaluate the probability that certain of our stock-based plans will meet targets established within the respective agreements and result in the vesting of such awards.  In addition, we derive an estimated forfeiture rate that is used in calculating the expense for these awards.                                                                                                                                                                              |   | See "Stock-Based Compensation." Comparisons to our stock price, a return on our stock price compared to certain stock indices or a return on equity calculation.                                                                                                                                        |
| Income taxes                                |   | We estimate the likelihood of the recoverability of our deferred tax assets (particularly, net operating loss carry-forwards).                                                                                                                                                                                                                                                                                                                                                   |   | See "Income Taxes." We examine our historical and projected operating results, review the eligible carry-forward period and tax planning opportunities and consider other relevant information. Changes in tax laws for the jurisdictions in which we operate could significantly impact our estimates. |
| Long-lived assets, intangibles and goodwill |   | We evaluate the recoverability of our assets periodically, but at least annually, by examining current and projected operating results to identify any triggering events, which may indicate impairment.  We compare the carrying value of the assets to a projection of fair value, utilizing judgment as to the identification of reportingunits, the allocation of corporate assets amongst reporting units and the determination of the appropriate discount rate. |   | See "Long-Lived Assets, Intangibles and Goodwill." Our impairment analysis is subjective and includes estimates based on assumptions regarding future growth rates, interest rates and operating expenses.                                                                                              |

Return to table of contents

----

|                                                               |   | Year Ended |    |   | % Change |   |
|--------------------------------------------------------------------|--------|------------|---------|--------|----------|--------|
| REVENUES:                                                          |   | 2009       |    |   | 2008     |   |   | 2007 |   |   |   | 2009/2008 |   |   |   | 2008/2007 |   |
| Services                                                           |   | $          | 553,772 |   |     |   | 79.6 | %  |   | $ | 597,695 |   |   |   | 76.5 | %  |   | $ | 508,046 |   |   |   | 75.8 | %  |   |   | (7.3 | %) |   |   | 17.6 | %  |
| Product Sales                                                      |   |       | 141,767 |   |     |   | 20.4 | %  |   |   | 183,141 |   |   |   | 23.5 | %  |   |   | 162,494 |   |   |   | 24.2 | %  |   |   | (22.6 | %) |   |   | 12.7 | %  |
|                                                               |   |       | 695,539 |   |     |   | 100.0 | %  |   |   | 780,836 |   |   |   | 100.0 | %  |   |   | 670,540 |   |   |   | 100.0 | %  |   |   | (10.9 | %) |   |   | 16.4 | %  |
| OPERATING EXPENSES:                                                |   |       |    |   |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Cost of services*                                                  |   |       | 352,039 |   |     |   | 63.6 | %  |   |   | 387,145 |   |   |   | 64.8 | %  |   |   | 336,155 |   |   |   | 66.2 | %  |   |   | (9.1 | %) |   |   | 15.2 | %  |
| Cost of product sales*                                             |   |       | 105,730 |   |     |   | 74.6 | %  |   |   | 127,637 |   |   |   | 69.7 | %  |   |   | 113,036 |   |   |   | 69.6 | %  |   |   | (17.2 | %) |   |   | 12.9 | %  |
| Total cost of services and product sales                           |   |       | 457,769 |   |     |   | 65.8 | %  |   |   | 514,782 |   |   |   | 65.9 | %  |   |   | 449,191 |   |   |   | 67.0 | %  |   |   | (11.1 | %) |   |   | 14.6 | %  |
| General and administrative expenses                                |   |       | 30,372  |   |     |   | 4.4 | %  |   |   | 31,646 |   |   |   | 4.1 | %  |   |   | 33,837 |   |   |   | 5.0 | %  |   |   | (4.0 | %) |   |   | (6.5 | %) |
| Depreciation and amortization                                      |   |       | 23,818  |   |     |   | 3.4 | %  |   |   | 21,773 |   |   |   | 2.8 | %  |   |   | 19,476 |   |   |   | 2.9 | %  |   |   | 9.4 | %  |   |   | 11.8 | %  |
| Other expense (income), net                                        |   |       | (3,202  | )      |     |   | (0.5 | %) |   |   | 5,580 |   |   |   | 0.7 | %  |   |   | (15,915 | ) |   |   | (2.3 | )% |   | NM |   |   | NM |   |
| OPERATING INCOME                                                   |   |       | 186,782 |   |     |   | 26.9 | %  |   |   | 207,055 |   |   |   | 26.5 | %  |   |   | 183,951 |   |   |   | 27.4 | %  |   |   | (9.8 | %) |   |   | 12.6 | %  |
| Gain on repurchase of senior exchangeable notes                    |   |       | -       |   |     |   | - | % |   |   | 2,829 |   |   |   | 0.4 | %  |   |   | - |   |   |   | - | %  |   |   | (100.0 | %) |   |   | 100.0 | %  |
| Interest expense                                                   |   |       | 15,523  |   |     |   | 2.3 | %  |   |   | 21,610 |   |   |   | 2.8 | %  |   |   | 18,379 |   |   |   | 2.7 | %  |   |   | (28.2 | %) |   |   | 17.6 | %  |
| Income before income tax expense                                   |   |       | 171,259 |   |     |   | 24.6 | %  |   |   | 188,274 |   |   |   | 24.1 | %  |   |   | 165,572 |   |   |   | 24.7 | %  |   |   | (9.0 | %) |   |   | 13.7 | %  |
| Income tax expense                                                 |   |       | 57,164  |   |     |   | 8.2 | %  |   |   | 56,766 |   |   |   | 7.3 | %  |   |   | 54,257 |   |   |   | 8.1 | %  |   |   | 0.7 | %  |   |   | 4.6 | %  |
| Net income                                                         |   |       | 114,095 |   |     |   | 16.4 | %  |   |   | 131,508 |   |   |   | 16.8 | %  |   |   | 111,315 |   |   |   | 16.6 | %  |   |   | (13.2 | %) |   |   | 18.1 | %  |
| Net income attributable to non-controlling interest                |   |       | 491     |   |     |   | 0.1 | %  |   |   | 342 |   |   |   | - | %  |   |   | 103 |   |   |   | - | % |   |   | 43.6 | %  |   |   | 232 | %  |
| Net income attributable to Core Laboratories N.V.                  |   | $          | 113,604 |   |     |   | 16.3 | %  |   | $ | 131,166 |   |   |   | 16.8 | %  |   | $ | 111,212 |   |   |   | 16.6 | % |   |   | (13.4 | %) |   |   | 17.9 | %  |
|                                                               |   |       |    |   |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| *Percentage based on applicable revenue rather than total revenue. |   |
| "NM" means not meaningful.                                         |   |

Return to table of contents

----

Return to table of contents

----

|                                  |   | Year Ended |   |
|---------------------------------------|--------|------------|--------|
|                                  |   | 2009       |   |   | 2008 |   |   | 2007 |   |
|                                  |   |       |   |   |   |   |   |   |   |
| Loss (gain) on sale of assets         |   | $          | 90     |   |   | $ | (2,015 | ) |   | $ | (10,354 | ) |
| Equity in loss (income) of affiliates |   |       | (92    | ) |   |   | (300 | ) |   |   | 656 |   |
| Foreign exchange loss (gain)          |   |       | (331   | ) |   |   | 6,555 |   |   |   | (1,413 | ) |
| Interest income                       |   |       | (138   | ) |   |   | (848 | ) |   |   | (1,282 | ) |
| Non-income tax expense (gain)         |   |       | (2,500 | ) |   |   | 5,030 |   |   |   | - |   |
| Other                                 |   |       | (231   | ) |   |   | (2,842 | ) |   |   | (3,522 | ) |
| Total other expense (income), net     |   | $          | (3,202 | ) |   | $ | 5,580 |   |   | $ | (15,915 | ) |
|                                  |   |       |   |   |   |   |   |   |   |   |   |   |

Return to table of contents

----

|   | Segment Analysis |
|--------|------------------|

|                         |   | For the Years Ended December 31, |    |
|------------------------------|--------|----------------------------------|---------|
|  (dollars in thousands) |   | 2009                             |    |   | % Change |   |   | 2008 |   |   | % Change |   |   | 2007 |   |
|                         |   |                             |    |   |   |   |   |   |   |   |   |   |   |   |   |
| Reservoir Description        |   | $                                | 414,934 |   |   |   | (4.7 | %) |   | $ | 435,425 |   |   |   | 16.3 | % |   | $ | 374,455 |   |
| Production Enhancement       |   |                             | 230,652 |   |   |   | (21.3 | %) |   |   | 293,017 |   |   |   | 19.7 | % |   |   | 244,830 |   |
| Reservoir Management         |   |                             | 49,953  |   |   |   | (4.7 | %) |   |   | 52,394 |   |   |   | 2.2 | % |   |   | 51,255 |   |
| Total Revenues               |   | $                                | 695,539 |   |   |   | (10.9 | %) |   | $ | 780,836 |   |   |   | 16.4 | % |   | $ | 670,540 |   |

|                                                                                                                |   | For the Years Ended December 31, |    |
|---------------------------------------------------------------------------------------------------------------------|--------|----------------------------------|---------|
|  (dollars in thousands)                                                                                        |   | 2009                             |    |   | % Change |   |   | 2008 |   |   | % Change |   |   | 2007 |   |
|                                                                                                                |   |                             |    |   |   |   |   |   |   |   |   |   |   |   |   |
| Reservoir Description (1)                                                                                           |   | $                                | 106,421 |   |   |   | 4.6 | %  |   | $ | 101,783 |   |   |   | 1.8 | % |   | $ | 99,950 |   |
| Production Enhancement                                                                                              |   |                             | 65,076  |   |   |   | (30.0 | %) |   |   | 93,025 |   |   |   | 35.0 | % |   |   | 68,917 |   |
| Reservoir Management                                                                                                |   |                             | 14,620  |   |   |   | (9.9 | %) |   |   | 16,224 |   |   |   | 10.7 | % |   |   | 14,650 |   |
| Corporate and other (3)                                                                                             |   |                             | 665     |   |   | NM (2) |   |   |   | (3,977 | ) |   | NM (2) |   |   |   | 434 |   |
|      Operating Income                                                                      |   | $                                | 186,782 |   |   |   | (9.8 | %) |   | $ | 207,055 |   |   |   | 12.6 | % |   | $ | 183,951 |   |
|                                                                                                                |   |                             |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| (1) 2007 results include a $10.2 million gain from sale of an asset.                                           |   |
| (2) "NM" means not meaningful.                                                                                 |   |
| (3) “Corporate and other" represents those items that are not directly relating to a particular segment. |   |

|                                                                   | For the Years Ended December 31, |
|------------------------------------------------------------------------|----------------------------------|
|                                                                   | 2009                             |   |   | 2008 |   |   | 2007 |
|                                                                   | Margin                           |   |   | Margin |   |   | Margin |
| Reservoir Description                                                  | 25.6%                            |   |   | 23.4% |   |   | 26.7% |
| Production Enhancement                                                 | 28.2%                            |   |   | 31.7% |   |   | 28.1% |
| Reservoir Management                                                   | 29.3%                            |   |   | 31.0% |   |   | 28.6% |
|    Total Company                                        | 26.9%                            |   |   | 26.5% |   |   | 27.4% |
|                                                                   |                             |   |   |   |   |   |   |
| (1)  Calculated by dividing "Operating Income" by "Revenue". |

Return to table of contents

----

Return to table of contents

----

|                                      |   | Year Ended December 31, |    |
|-------------------------------------------|--------|-------------------------|---------|
| Free Cash Flow Calculation                |   | 2009                    |    |   | 2008 |   |   | 2007 |   |
| Net cash provided by operating activities |   | $                       | 181,873 |   |   | $ | 155,207 |   |   | $ | 125,695 |   |
| Less: capital expenditures                |   |                    | (17,289 | ) |   |   | (30,950 | ) |   |   | (23,827 | ) |
| Free cash flow                            |   | $                       | 164,584 |   |   | $ | 124,257 |   |   | $ | 101,868 |   |

|                                    |   | Year Ended December 31, |    |
|-----------------------------------------|--------|-------------------------|---------|
|                                    |   | 2009                    |    |   | 2008 |   |   | 2007 |   |
| Cash provided by/(used in):             |   |                    |    |
| Operating activities                    |   | $                       | 181,873 |   |   | $ | 155,207 |   |   | $ | 125,695 |   |
| Investing activities                    |   |                    | (18,540 | ) |   |   | (41,108 | ) |   |   | (19,975 | ) |
| Financing activities                    |   |                    | (18,426 | ) |   |   | (103,578 | ) |   |   | (134,326 | ) |
| Net change in cash and cash equivalents |   | $                       | 144,907 |   |   | $ | 10,521 |   |   | $ | (28,606 | ) |

Return to table of contents

----

|                                                                                                                                                                                                          |   | Total  |    |   | Less than 1 year |   |   | 1-3 Years |   |   | 3-5 Years |   |   | More than5 Years |    |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|---------|--------|------------------|--------|--------|-----------|--------|--------|-----------|--------|--------|------------------|---------|
| Contractual Obligations:                                                                                                                                                                                      |   |   |    |
|                                                                                                                                                                                                          |   |   |    |   |             |   |   |      |   |   |      |   |   |             |    |
| Long-term debt (1)                                                                                                                                                                                            |   | $      | 238,658 |   |             | $      | -      |      |   | $      | 238,658   |   |   | $                |  - |   |   | $ | - |   |
| Operating leases                                                                                                                                                                                              |   |   | 23,930  |   |             |   | 6,682  |      |   |   | 8,809     |   |   |             | 4,706   |   |   |   | 3,733 |   |
| Pension (2)                                                                                                                                                                                                   |   |   | 2,721   |   |             |   | 2,721  |      |   |   | -         |   |   |             | -       |   |   |   | - |   |
|     Total contractual obligations                                                                                                                                                         |   | $      | 265,309 |   |             | $      | 9,403  |      |   | $      | 247,467   |   |   | $                | 4,706   |   |   | $ | 3,733 |   |
|                                                                                                                                                                                                          |   |   |    |   |             |   |   |      |   |   |      |   |   |             |    |   |   |   |   |   |
| (1) Not included in the above balances are anticipated cash payments for interest of $0.6 million a year for 2010-2011 for a total of $1.2 million on the long-term debt that is due November 2011. |   |
| (2) Our Dutch pension plan requires annual employer contributions. Amounts payable in the future will be based on future workforce factors which cannot be projected beyond one year.          |   |

Return to table of contents

----

| -      | our ability to continue to develop or acquire new and useful technology;                                                    |
|--------|-----------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                        |
| -      | the realization of anticipated synergies from acquired businesses and future acquisitions;                                  |
|   |                                                                                                                        |
| -      | our dependence on one industry, oil and gas, and the impact of commodity prices on the expenditure levels of our customers; |
|   |                                                                                                                        |
| -      | competition in the markets we serve;                                                                                        |

Return to table of contents

----

| -      | the risks and uncertainties attendant to adverse industry, political, economic and financial market conditions, including stock prices, government regulations, interest rates and credit availability; |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                    |
| -      | unsettled political conditions, war, civil unrest, currency controls and governmental actions in the numerous countries in which we operate;                                                            |
|   |                                                                                                                                                                                                    |
| -      | changes in the price of oil and natural gas;                                                                                                                                                            |
|   |                                                                                                                                                                                                    |
| -      | integration of acquired businesses; and                                                                                                                                                                 |
|   |                                                                                                                                                                                                    |
| -      | the effects of industry consolidation.                                                                                                                                                                  |

ITEM 7A

|                       |   | Year Ended December 31, |   |
|----------------------------|--------|-------------------------|--------|
| Losses (gains) by currency |   | 2009                    |   |   | 2008 |   |   | 2007 |   |
|                       |   |                    |   |   |   |   |   |   |   |
| Australian Dollar          |   | $                       | (438   | ) |   | $ | 654 |   |   | $ | (15 | ) |
| British Pound              |   |                    | (106   | ) |   |   | 654 |   |   |   | 48 |   |
| Canadian Dollar            |   |                    | (1,686 | ) |   |   | 2,706 |   |   |   | (637 | ) |
| Euro                       |   |                    | (81    | ) |   |   | (132 | ) |   |   | (374 | ) |
| Mexican Peso               |   |                    | (99    | ) |   |   | 683 |   |   |   | 73 |   |
| Russian Ruble              |   |                    | 421    |   |   |   | 688 |   |   |   | (562 | ) |
| Venezuelan Bolivar         |   |                    | 1,335  |   |   |   | (2 | ) |   |   | 6 |   |
| Other currencies           |   |                    | 323    |   |   |   | 1,304 |   |   |   | 48 |   |
| Total losses (gains)       |   | $                       | (331   | ) |   | $ | 6,555 |   |   | $ | (1,413 | ) |

Return to table of contents

----

ITEM 8.

ITEM 9

ITEM 9A

Return to table of contents

----

ITEM 9B

PART III

Return to table of contents

----

ITEM 15

| (a) | Financial Statements |
|-----|----------------------|

|                                                                                              | Page   |
|---------------------------------------------------------------------------------------------------|--------|
|                                                                                              |   |
| Report of Independent Registered Public Accounting Firm-PricewaterhouseCoopers LLP                | F-1    |
| Consolidated Balance Sheets as of December 31, 2009 and 2008                                      | F-2    |
| Consolidated Statements of Operations for the Years Ended December 31, 2009, 2008 and 2007        | F-3    |
| Consolidated Statements of Changes in Equity for the Years Ended December 31, 2009, 2008 and 2007 | F-4    |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2009, 2008 and 2007        | F-6    |
| Notes to Consolidated Financial Statements                                                        | F-7    |

Schedule II - Valuation and Qualifying Account

| (b) | Exhibits |
|-----|----------|

| Exhibit No. |   | Exhibit Title                                                                                                                                                                                                                          |   | Incorporated by Reference from the Following Documents                |
|-------------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-----------------------------------------------------------------------|
|        |   |                                                                                                                                                                                                                                   |   |                                                                  |
| 3.1         | -      | Articles of Association of the Company, as amended (including English translation)                                                                                                                                                     |   | Form F-1, September 20, 1995 (File No. 000-26710)                     |
|        |   |                                                                                                                                                                                                                                   |   |                                                                  |
| 3.2         | -      | Amendments to the Articles of Association of Core Laboratories N.V.                                                                                                                                                                    |   | Proxy Statement dated May 17, 2006 for Annual Meeting of Shareholders |
|        |   |                                                                                                                                                                                                                                   |   |                                                                  |
| 4.1         | -      | Form of certificate representing Common Shares                                                                                                                                                                                         |   | Form 10-K, March 31, 1999 (File No. 001-14273)                        |
|        |   |                                                                                                                                                                                                                                   |   |                                                                  |
| 4.2         | -      | Purchase Agreement, dated October 31, 2006 among Core Laboratories LP, Core Laboratories N.V., Lehman Brothers Inc. and Banc of America Securities LLC                                                                                 |   | Form 8-K, November 6, 2006 (File No. 001-14273)                       |
|        |   |                                                                                                                                                                                                                                   |   |                                                                  |
| 4.3         | -      | Indenture, dated November 6, 2006, among Core Laboratories LP, as Issuer, Core Laboratories N.V., as guarantor, and Wells Fargo Bank, National Association, as trustee, including the form of 0.25% Senior Exchangeable Notes due 2011 |   | Form 8-K, November 6, 2006 (File No. 001-14273)                       |
|        |   |                                                                                                                                                                                                                                   |   |                                                                  |
| 4.4         | -      | Registration Rights Agreement, dated as of November 6, 2006, among Core Laboratories LP, Core Laboratories N.V., Lehman Brothers Inc. and Banc of America Securities LLC                                                               |   | Form 8-K, November 6, 2006 (File No. 001-14273)                       |
|        |   |                                                                                                                                                                                                                                   |   |                                                                  |
| 4.5         | -      | Note Hedge Confirmation, dated October 31, 2006, among Core Laboratories LP, and Lehman Brothers OTC Derivatives Inc.                                                                                                                  |   | Form 8-K, November 6, 2006 (File No. 001-14273)                       |
|        |   |                                                                                                                                                                                                                                   |   |                                                                  |
| 4.6         | -      | Warrant Confirmation, dated October 31, 2006 among Core Laboratories N.V. and Lehman Brothers OTC Derivatives Inc.                                                                                                                     |   | Form 8-K, November 6, 2006 (File No. 001-14273)                       |
|        |   |                                                                                                                                                                                                                                   |   |                                                                  |
| 4.7         | -      | Amendment to Note Hedge Confirmation, dated November 15, 2006, among Core Laboratories LP, and Lehman Brothers OTC Derivatives Inc.                                                                                                    |   | Form 8-K, November 20, 2006 (File No. 001-14273)                      |
|        |   |                                                                                                                                                                                                                                   |   |                                                                  |
| 4.8         | -      | Amendment to Warrant Confirmation, dated November 15, 2006 among Core Laboratories N.V. and Lehman Brothers OTC Derivatives Inc.                                                                                                       |   | Form 8-K, November 20, 2006 (File No. 001-14273)                      |

Return to table of contents

----

|   |   |                                                                                                                                                                                                                                                                  |   |                                                                                         |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|----------------------------------------------------------------------------------------------|
| 10.1   | -      | Core Laboratories N.V. 1995 Long-Term Incentive Plan (as amended and restated effective as of May 29, 1997)                                                                                                                                                           |   | Proxy Statement dated April 28, 1997 for Annual Meeting of Shareholders (File No. 000-26710) |
|   |   |                                                                                                                                                                                                                                                                  |   |                                                                                         |
| 10.2   | -      | Form of Indemnification Agreement to be entered into by the Company and certain of its directors and officers                                                                                                                                                         |   | Form F-1, September 20, 1995 (File No. 000-26710)                                            |
|   |   |                                                                                                                                                                                                                                                                  |   |                                                                                         |
| 10.3   | -      | Amended and Restated Credit Agreement among Core Laboratories N.V., Core Laboratories, Inc., Core Laboratories (U.K.) Limited, Bankers Trust Company, NationsBank, N.A. and the Bank Group, dated as of July 18, 1997                                                 |   | Form S-3, October 31, 1997 (File No. 333-39265)                                              |
|   |   |                                                                                                                                                                                                                                                                  |   |                                                                                         |
| 10.4   | -      | Core Laboratories Supplemental Executive Retirement Plan effective as of January 1, 19981                                                                                                                                                                             |   | Form 10-K, March 31, 1998 (File No. 000-26710)                                               |
|   |   |                                                                                                                                                                                                                                                                  |   |                                                                                         |
| 10.5   | -      | Core Laboratories Supplemental Executive Retirement Plan for Monty L. Davis effective January 1, 19991                                                                                                                                                                |   | Form 10-Q, August 16, 1999 (File No. 001-14273)                                              |
|   |   |                                                                                                                                                                                                                                                                  |   |                                                                                         |
| 10.6   | -      | Amendment to Core Laboratories Supplemental Executive Retirement Plan filed January 1, 1998, effective July 29, 19991                                                                                                                                                 |   | Form 10-Q, August 16, 1999 (File No. 001-14273)                                              |
|   |   |                                                                                                                                                                                                                                                                  |   |                                                                                         |
| 10.7   | -      | Note and Guarantee Agreement by Core Laboratories, Inc. for Guaranteed Senior Notes, Series A, and Guaranteed Senior Notes, Series B, dated as of July 22, 1999                                                                                                       |   | Form 10-Q, August 16, 1999 (File No. 001-14273)                                              |
|   |   |                                                                                                                                                                                                                                                                  |   |                                                                                         |
| 10.8   | -      | First Amendment to Core Laboratories N.V. 1995 Long-Term Incentive Plan (as amended and restated effective as of May 29, 1997)                                                                                                                                        |   | Form 10-K, March 15, 2001 (File No. 001-14273)                                               |
|   |   |                                                                                                                                                                                                                                                                  |   |                                                                                         |
| 10.9   | -      | Amendment to Core Laboratories N.V. 1995 Long-Term Incentive Plan (as Amended and Restated Effective as of May 29, 1997)                                                                                                                                              |   | Form 10-Q, May 15, 2003 (File No. 001-14273)                                                 |
|   |   |                                                                                                                                                                                                                                                                  |   |                                                                                         |
| 10.10  | -      | Amendment to Core Laboratories Supplement Executive Retirement Plan1                                                                                                                                                                                                  |   | Form 10-Q, May 15, 2003 (File No. 001-14273)                                                 |
|   |   |                                                                                                                                                                                                                                                                  |   |                                                                                         |
| 10.11  | -      | Amendment to Restated Employment Agreement dated December 31, 2001 between Core Laboratories N.V. and David Demshur1                                                                                                                                                  |   | Form 10-Q, May 15, 2003 (File No. 001-14273)                                                 |
|   |   |                                                                                                                                                                                                                                                                  |   |                                                                                         |
| 10.12  | -      | Amendment to Restated Employment Agreement dated December 31, 2001 between Core Laboratories N.V. and Richard L. Bergmark1                                                                                                                                            |   | Form 10-Q, May 15, 2003 (File No. 001-14273)                                                 |
|   |   |                                                                                                                                                                                                                                                                  |   |                                                                                         |
| 10.13  | -      | Amendment to Restated Employment Agreement dated December 31, 2001 between Core Laboratories N.V. and Monty L. Davis1                                                                                                                                                 |   | Form 10-Q, May 15, 2003 (File No. 001-14273)                                                 |
|   |   |                                                                                                                                                                                                                                                                  |   |                                                                                         |
| 10.14  | -      | Non-Employee Director Compensation Summary                                                                                                                                                                                                                            |   | From 10-K, February 20, 2008 (File No. 001-14273)                                            |
|   |   |                                                                                                                                                                                                                                                                  |   |                                                                                         |
| 10.15  | -      | Third Amended and Restated Credit Agreement among Core Laboratories N.V., Core Laboratories LP, JP Morgan Chase Bank, N.A., Bank of America, N.A., JP Morgan Securities Inc. and Banc of America Securities LLC, dated as of March 24, 2005                           |   | Form 10-Q, May 4, 2005 (File No. 001-14273)                                                  |
|   |   |                                                                                                                                                                                                                                                                  |   |                                                                                         |
| 10.16  | -      | First Amendment to the Third Amended and Restated Credit Agreement among Core Laboratories N.V., Core Laboratories LP, JP Morgan Chase Bank, N.A., Bank of America, N.A., JP Morgan Securities Inc. and Banc of America Securities LLC, dated as of December 20, 2005 |   | Form 8-K, December 23, 2005 (File No. 001-14273)                                             |
|   |   |                                                                                                                                                                                                                                                                  |   |                                                                                         |
| 10.17  | -      | Core Laboratories N.V. 2006 Nonemployee Director Stock Incentive Plan                                                                                                                                                                                                 |   | Proxy Statement dated May 17, 2006 for Annual Meeting of Shareholders                        |

Return to table of contents

----

|                                                           |   |                                                                                                                                                                                                                                                                 |   |                                              |
|----------------------------------------------------------------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------------------------------------|
| 10.18                                                          | -      | Second Amendment to the Third Amended and Restated Credit Agreement among Core Laboratories N.V., Core Laboratories LP, JP Morgan Chase Bank, N.A., Bank of America, N.A., JP Morgan Securities Inc. and Banc of America Securities LLC, dated as of July 7, 2006    |   | Form 8-K, November 7, 2006 (File No. 001-14273)   |
|                                                           |   |                                                                                                                                                                                                                                                                 |   |                                              |
| 10.19                                                          | -      | Third Amendment to the Third Amended and Restated Credit Agreement among Core Laboratories N.V., Core Laboratories LP, JP Morgan Chase Bank, N.A., Bank of America, N.A., JP Morgan Securities Inc. and Banc of America Securities LLC, dated as of November 6, 2006 |   | Form 8-K, November 7, 2006 (File No. 001-14273)   |
|                                                           |   |                                                                                                                                                                                                                                                                 |   |                                              |
| 10.20                                                          | -      | Form of Director Performance Share Award Restricted Share Agreement (ROE Based) 1                                                                                                                                                                                    |   | Form 10-K, February 20, 2007 (File No. 001-14273) |
|                                                           |   |                                                                                                                                                                                                                                                                 |   |                                              |
| 10.21                                                          | -      | Form of Restricted Share Award Program Agreement1                                                                                                                                                                                                                    |   | Form 10-K, February 20, 2007 (File No. 001-14273) |
|                                                           |   |                                                                                                                                                                                                                                                                 |   |                                              |
| 10.22                                                          | -      | Fourth Amended and Restated Credit Agreement among Core Laboratories N.V., Core Laboratories LP, Bank of America, N.A., and Banc of America Securities LLC, dated as of January 22, 2008                                                                             |   | Form 8-K, January 23, 2008 (File No. 001-14273)   |
|                                                           |   |                                                                                                                                                                                                                                                                 |   |                                              |
| 10.23                                                          | -      | Form of Restated Employment Agreement between Core Laboratories N.V. and David M. Demshur dated as of December 31, 20071                                                                                                                                             |   | Form 10-Q, May 12, 2008 (File No. 001-14273)      |
|                                                           |   |                                                                                                                                                                                                                                                                 |   |                                              |
| 10.24                                                          | -      | Form of Restated Employment Agreement between Core Laboratories N.V. and Richard L. Bergmark dated as of December 31, 20071                                                                                                                                          |   | Form 10-Q, May 12, 2008 (File No. 001-14273)      |
|                                                           |   |                                                                                                                                                                                                                                                                 |   |                                              |
| 10.25                                                          | -      | Form of Restated Employment Agreement between Core Laboratories N.V. and Monty L. Davis dated as of December 31, 20071                                                                                                                                               |   | Form 10-Q, May 12, 2008 (File No. 001-14273)      |
|                                                           |   |                                                                                                                                                                                                                                                                 |   |                                              |
| 10.26                                                          |   | Amendment to Core Laboratories Supplemental Executive Retirement Plan dated as of March 5, 20081                                                                                                                                                                     |   | Form 10-Q, May 12, 2008 (File No. 001-14273)      |
|                                                           |   |                                                                                                                                                                                                                                                                 |   |                                              |
| 10.27                                                          |   | Amendment to Core Laboratories Supplemental Executive Retirement Plan for Monty L. Davis dated as of March 5, 20081                                                                                                                                                  |   | Form 10-Q, May 12, 2008 (File No. 001-14273)      |
|                                                           |   |                                                                                                                                                                                                                                                                 |   |                                              |
| 21.1                                                           | -      | Subsidiaries of the Registrant                                                                                                                                                                                                                                       |   | Filed Herewith                                    |
|                                                           |   |                                                                                                                                                                                                                                                                 |   |                                              |
| 23.1                                                           | -      | Consent of PricewaterhouseCoopers LLP                                                                                                                                                                                                                                |   | Filed Herewith                                    |
|                                                           |   |                                                                                                                                                                                                                                                                 |   |                                              |
| 31.1                                                           | -      | Certification of Chief Executive Officer Pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002                                                                                        |   | Filed Herewith                                    |
|                                                           |   |                                                                                                                                                                                                                                                                 |   |                                              |
| 31.2                                                           | -      | Certification of Chief Financial Officer Pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002                                                                                        |   | Filed Herewith                                    |
|                                                           |   |                                                                                                                                                                                                                                                                 |   |                                              |
| 32.1                                                           | -      | Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002                                                                                                                    |   | Furnished Herewith                                |
|                                                           |   |                                                                                                                                                                                                                                                                 |   |                                              |
| 32.2                                                           | -      | Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002                                                                                                                    |   | Furnished Herewith                                |
|                                                           |   |                                                                                                                                                                                                                                                                 |   |                                              |
| 1) Management contracts or compensatory plans or arrangements. |

Return to table of contents

----

|                    |   | CORE LABORATORIES N.V.                                              |
|-------------------------|--------|---------------------------------------------------------------------|
|                    |   | By its sole managing director, Core Laboratories International B.V. |
|                    |   |                                                                |
| Date: February 19, 2010 | By:    | /s/ JAN WILLEM SODDERLAND                                           |
|                    |   | Jan Willem Sodderland                                               |
|                    |   | Managing Director of Core Laboratories International B.V.           |

|  Signature           |   |  Title                                 |
|---------------------------|--------|---------------------------------------------|
|                      |   |                                        |
| /s/ DAVID M. DEMSHUR      |   | President, Chief Executive Officer,         |
| David M. Demshur          |   | Chairman and Supervisory Director           |
|                      |   |                                        |
| /s/ RICHARD L. BERGMARK   |   | Executive Vice President, Chief             |
| Richard L. Bergmark       |   | Financial Officer, Treasurer and            |
|                      |   | Supervisory Director                        |
|                      |   |                                        |
| /s/ C. BRIG MILLER        |   | Vice President and Chief Accounting Officer |
| C. Brig Miller            |   |                                        |
|                      |   |                                        |
| /s/ JOSEPH R. PERNA       |   | Supervisory Director                        |
| Joseph R. Perna           |   |                                        |
|                      |   |                                        |
| /s/ JACOBUS SCHOUTEN      |   | Supervisory Director                        |
| Jacobus Schouten          |   |                                        |
|                      |   |                                        |
| /s/ RENE R. JOYCE         |   | Supervisory Director                        |
| Rene R. Joyce             |   |                                        |
|                      |   |                                        |
| /s/ MICHAEL C. KEARNEY    |   | Supervisory Director                        |
| Michael C. Kearney        |   |                                        |
|                      |   |                                        |
| /s/ D. JOHN OGREN         |   | Supervisory Director                        |
| D. John Ogren             |   |                                        |
|                      |   |                                        |
| /s/ ALEXANDER VRIESENDORP |   | Supervisory Director                        |
| Alexander Vriesendorp     |   |                                        |
|                      |   |                                        |

Return to table of contents

----

Report of Independent Registered Public Accounting Firm

----

CONSOLIDATED BALANCE SHEETS

|                                                                        |   | 2009   |     |   | 2008   |   |
|-----------------------------------------------------------------------------|--------|--------|----------|--------|--------|--------|
| ASSETS                                                                      |   |   |     |   |   |   |
| CURRENT ASSETS:                                                             |   |   |     |   |   |   |
| Cash and cash equivalents                                                   |   | $      | 181,045  |   |   | $      | 36,138 |   |
| Accounts receivable, net of allowance for doubtful accounts of $3,202 and   |   |   |     |   |   |   |   |   |
|   $3,535 at 2009 and 2008, respectively                           |   |   | 133,758  |   |   |   | 144,293 |   |
| Inventories, net                                                            |   |   | 32,184   |   |   |   | 34,838 |   |
| Prepaid expenses and other current assets                                   |   |   | 43,550   |   |   |   | 20,376 |   |
| TOTAL CURRENT ASSETS                                                        |   |   | 390,537  |   |   |   | 235,645 |   |
|                                                                        |   |   |     |   |   |   |   |   |
| PROPERTY, PLANT AND EQUIPMENT, net                                          |   |   | 98,784   |   |   |   | 103,463 |   |
| INTANGIBLES, net                                                            |   |   | 6,520    |   |   |   | 6,992 |   |
| GOODWILL                                                                    |   |   | 148,600  |   |   |   | 148,600 |   |
| DEFERRED TAX ASSET                                                          |   |   | -        |   |   |   | 17,708 |   |
| OTHER ASSETS                                                                |   |   | 13,725   |   |   |   | 9,127 |   |
| TOTAL ASSETS                                                                |   | $      | 658,166  |   |   | $      | 521,535 |   |
|                                                                        |   |   |     |   |   |   |   |   |
| LIABILITIES AND EQUITY                                                      |   |   |     |   |   |   |   |   |
| CURRENT LIABILITIES:                                                        |   |   |     |   |   |   |   |   |
| Accounts payable                                                            |   | $      | 33,009   |   |   | $      | 41,588 |   |
| Accrued payroll and related costs                                           |   |   | 24,368   |   |   |   | 28,637 |   |
| Taxes other than payroll and income                                         |   |   | 8,183    |   |   |   | 7,949 |   |
| Unearned revenues                                                           |   |   | 16,528   |   |   |   | 7,932 |   |
| Income taxes payable                                                        |   |   | 15,433   |   |   |   | - |   |
| Other accrued expenses                                                      |   |   | 8,887    |   |   |   | 9,584 |   |
| TOTAL CURRENT LIABILITIES                                                   |   |   | 106,408  |   |   |   | 95,690 |   |
|                                                                        |   |   |     |   |   |   |   |   |
| LONG-TERM DEBT AND CAPITAL LEASE OBLIGATIONS                                |   |   | 209,112  |   |   |   | 194,568 |   |
| DEFERRED COMPENSATION                                                       |   |   | 16,866   |   |   |   | 12,815 |   |
| DEFERRED TAX LIABILITIES                                                    |   |   | 7,692    |   |   |   | - |   |
| OTHER LONG-TERM LIABILITIES                                                 |   |   | 36,330   |   |   |   | 30,177 |   |
| COMMITMENTS AND CONTINGENCIES                                               |   |   |     |   |   |   |   |   |
|  EQUITY:                                                               |   |   |     |   |   |   |   |   |
| Preference shares, EUR 0.04 par value;                                      |   |   |     |   |   |   |   |   |
| 3,000,000 shares authorized, none issued or outstanding                     |   |   | -        |   |   |   | - |   |
| Common shares, EUR 0.04 par value;                                          |   |   |     |   |   |   |   |   |
| 100,000,000 shares authorized, 25,519,956 issued and 22,986,704 outstanding |   |   |     |   |   |   |   |   |
| at 2009 and 25,519,956 issued and 23,020,033 outstanding at 2008            |   |   | 1,430    |   |   |   | 1,430 |   |
| Additional paid-in capital                                                  |   |   | 61,719   |   |   |   | 53,019 |   |
| Retained earnings                                                           |   |   | 469,454  |   |   |   | 382,266 |   |
| Accumulated other comprehensive income (loss)                               |   |   | (6,536   | )      |   |   | (4,927 | ) |
| Treasury shares (at cost), 2,533,252 at 2009 and 2,499,923 at 2008          |   |   | (246,699 | )      |   |   | (245,661 | ) |
| Total Core Laboratories N.V. shareholders’ equity                     |   |   | 279,368  |   |   |   | 186,127 |   |
| Non-controlling interest                                                    |   |   | 2,390    |   |   |   | 2,158 |   |
| TOTAL EQUITY                                                                |   |   | 281,758  |   |   |   | 188,285 |   |
| TOTAL LIABILITIES AND EQUITY                                                |   | $      | 658,166  |   |   | $      | 521,535 |   |

Return to index

----

CONSOLIDATED STATEMENTS OF OPERATIONS

|                                                              |   | 2009   |    |   | 2008   |   |    | 2007   |   |
|-------------------------------------------------------------------|--------|--------|---------|--------|--------|--------|---------|--------|--------|
|                                                              |   |   |    |   |   |   |    |   |   |
| REVENUES:                                                         |   |   |    |   |   |   |    |   |   |
| Services                                                          |   | $      | 553,772 |   |   | $      | 597,695 |   |   | $ | 508,046 |   |
| Product sales                                                     |   |   | 141,767 |   |   |   | 183,141 |   |   |   | 162,494 |   |
|                                                              |   |   | 695,539 |   |   |   | 780,836 |   |   |   | 670,540 |   |
| OPERATING EXPENSES:                                               |   |   |    |   |   |   |    |   |   |   |   |   |
| Cost of services, exclusive of depreciation shown below           |   |   | 352,039 |   |   |   | 387,145 |   |   |   | 336,155 |   |
| Cost of product sales, exclusive of depreciation shown below      |   |   | 105,730 |   |   |   | 127,637 |   |   |   | 113,036 |   |
| General and administrative expenses                               |   |   | 30,372  |   |   |   | 31,646  |   |   |   | 33,837 |   |
| Depreciation                                                      |   |   | 23,106  |   |   |   | 21,063  |   |   |   | 18,791 |   |
| Amortization                                                      |   |   | 712     |   |   |   | 710     |   |   |   | 685 |   |
| Other expense (income), net                                       |   |   | (3,202  | )      |   |   | 5,580   |   |   |   | (15,915 | ) |
| OPERATING INCOME                                                  |   |   | 186,782 |   |   |   | 207,055 |   |   |   | 183,951 |   |
| Gain on repurchase of senior exchangeable notes                   |   |   | -       |   |   |   | 2,829   |   |   |   | - |   |
| Interest expense                                                  |   |   | 15,523  |   |   |   | 21,610  |   |   |   | 18,379 |   |
| Income before income tax expense                                  |   |   | 171,259 |   |   |   | 188,274 |   |   |   | 165,572 |   |
| Income tax expense                                                |   |   | 57,164  |   |   |   | 56,766  |   |   |   | 54,257 |   |
| Net income                                                        |   |   | 114,095 |   |   |   | 131,508 |   |   |   | 111,315 |   |
| Net income attributable to non-controlling interest               |   |   | 491     |   |   |   | 342     |   |   |   | 103 |   |
| Net income attributable to Core Laboratories N.V.                 |   | $      | 113,604 |   |   | $      | 131,166 |   |   | $ | 111,212 |   |
|  EARNINGS PER SHARE INFORMATION:                             |   |   |    |   |   |   |    |   |   |   |   |   |
|                                                              |   |   |    |   |   |   |    |   |   |   |   |   |
| Basic earnings per share attributable to Core Laboratories N.V.   |   | $      | 4.95    |   |   | $      | 5.70    |   |   | $ | 4.72 |   |
|                                                              |   |   |    |   |   |   |    |   |   |   |   |   |
|                                                              |   |   |    |   |   |   |    |   |   |   |   |   |
| Diluted earnings per share attributable to Core Laboratories N.V. |   | $      | 4.87    |   |   | $      | 5.48    |   |   | $ | 4.56 |   |
|                                                              |   |   |    |   |   |   |    |   |   |   |   |   |
| Cash dividends per share                                          |   | $      | 1.15    |   |   | $      | 1.20    |   |   | $ | - |   |
|                                                              |   |   |    |   |   |   |    |   |   |   |   |   |
| WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:                       |   |   |    |   |   |   |    |   |   |   |   |   |
| Basic                                                             |   |   | 22,969  |   |   |   | 23,008  |   |   |   | 23,537 |   |
| Diluted                                                           |   |   | 23,328  |   |   |   | 23,944  |   |   |   | 24,408 |   |
|                                                              |   |   |    |   |   |   |    |   |   |   |   |   |
|                                                              |   |   |    |   |   |   |    |   |   |   |   |   |

Return to index

----

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

|                                                                                 |   |          |       |   |       |   |   |    |   |   |     |   |   | Accumulated    |     |   |      |   |   |   |   |   |        |   |   |   |     |
|--------------------------------------------------------------------------------------|--------|---------------|------------|--------|------------|--------|--------|---------|--------|--------|----------|--------|--------|----------------|----------|--------|-----------|--------|--------|--------|--------|--------|-------------|--------|--------|--------|----------|
|                                                                                 |   | Common Shares |       |   | Additional |   |   |    |   |   | Other    |   |   | Treasury Stock |     |   | Non-      |   |   |   |   |
|                                                                                 |   | Number of     |       |   | Par        |   |   | Paid-In |   |   | Retained |   |   | Comprehensive  |     |   | Number of |   |   |   |   |   | Controlling |   |   | Total  |     |
|                                                                                 |   | Shares        |       |   | Value      |   |   | Capital |   |   | Earnings |   |   | Income (Loss)  |     |   | Shares    |   |   | Amount |   |   | Interest    |   |   | Equity |     |
| BALANCE, December 31, 2006                                                           |   |          | 25,608,511 |   |       | $      | 1,450  |    |   | $      | 23,182   |   |   | $              | 224,110  |   |      | $      | (2,072 | )      |   |   | 2,383,390   |   |   | $      | (174,834 | ) |   | $ | 1,446 |   |   | $ | 73,282 |   |
| Change in accounting principle                                                       |   |          | -          |   |       |   | -      |    |   |   | 55,907   |   |   |           | (1,617   | )      |      |   | -      |   |   |   | -           |   |   |   | -        |   |   |   | - |   |   |   | 54,290 |   |
| Stock options exercised, net of capital taxes                                   |   |          | 1,426,135  |   |       |   | 76     |    |   |   | 18,378   |   |   |           | -        |   |      |   | -      |   |   |   | -           |   |   |   | -        |   |   |   | - |   |   |   | 18,454 |   |
| Stock-based compensation, net of awards issued                                       |   |          | 229,650    |   |       |   | 12     |    |   |   | 4,655    |   |   |           | -        |   |      |   | -      |   |   |   | -           |   |   |   | -        |   |   |   | - |   |   |   | 4,667 |   |
| Tax benefit of stock-based awards issued                                             |   |          | -          |   |       |   | -      |    |   |   | 28,936   |   |   |           | -        |   |      |   | -      |   |   |   | -           |   |   |   | -        |   |   |   | - |   |   |   | 28,936 |   |
| Initial adoption of new standards related to accounting for income tax uncertainties |   |          | -          |   |       |   | -      |    |   |   | -        |   |   |           | (3,341   | )      |      |   | -      |   |   |   | -           |   |   |   | -        |   |   |   | - |   |   |   | (3,341 | ) |
| Repurchases of common shares                                                         |   |          | -          |   |       |   | -      |    |   |   | -        |   |   |           | -        |   |      |   | -      |   |   |   | 1,814,957   |   |   |   | (181,812 | ) |   |   | - |   |   |   | (181,812 | ) |
| Cancellation of common shares                                                        |   |          | (4,183,347 | )      |       |   | (238   | )       |   |   | (75,151  | )      |   |           | (279,378 | )      |      |   | -      |   |   |   | (4,183,347  | )      |   |   | 354,767  |   |   |   | - |   |   |   | - |   |
| Non-controlling interest dividend                                                    |   |          | -          |   |       |   | -      |    |   |   | -        |   |   |           | -        |   |      |   | -      |   |   |   | -           |   |   |   | -        |   |   |   | (63 | ) |   |   | (63 | ) |
| Comprehensive income:                                                                |   |          |       |   |       |   |   |    |   |   |     |   |   |           |     |   |      |   |   |   |   |   |        |   |   |   |     |   |   |   |   |   |   |   |   |   |
| Adjustment of unrecognized pension actuarial gain, net of $768 tax                   |   |          | -          |   |       |   | -      |    |   |   | -        |   |   |           | -        |   |      |   | 2,244  |   |   |   | -           |   |   |   | -        |   |   |   | - |   |   |   | 2,244 |   |
| Amortization of prior service cost and transition asset, net of $21 tax              |   |          | -          |   |       |   | -      |    |   |   | -        |   |   |           | -        |   |      |   | 54     |   |   |   | -           |   |   |   | -        |   |   |   | - |   |   |   | 54 |   |
| Net income                                                                           |   |          | -          |   |       |   | -      |    |   |   | -        |   |   |           | 111,212  |   |      |   | -      |   |   |   | -           |   |   |   | -        |   |   |   | 103 |   |   |   | 111,315 |   |
|   Total comprehensive income                                               |   |          |       |   |       |   |   |    |   |   |     |   |   |           |     |   |      |   |   |   |   |   |        |   |   |   |     |   |   |   |   |   |   |   | 113,613 |   |
|                                                                                 |   |          |       |   |       |   |   |    |   |   |     |   |   |           |     |   |      |   |   |   |   |   |        |   |   |   |     |   |   |   |   |   |   |   |   |   |
| BALANCE, December 31, 2007                                                           |   |          | 23,080,949 |   |       | $      | 1,300  |    |   | $      | 55,907   |   |   | $              | 50,986   |   |      | $      | 226    |   |   |   | 15,000      |   |   | $      | (1,879   | ) |   | $ | 1,486 |   |   | $ | 108,026 |   |

Return to index

----

|                                                                    |   |               |       |   |       |   |   |    |   |   |     |   |   | Accumulated    |    |   |      |   |   |    |   |   |        |   |   |   |     |
|-------------------------------------------------------------------------|--------|--------------------|------------|--------|------------|--------|--------|---------|--------|--------|----------|--------|--------|----------------|---------|--------|-----------|--------|--------|---------|--------|--------|-------------|--------|--------|--------|----------|
|                                                                    |   | Common Shares |       |   | Additional |   |   |    |   |   | Other    |   |   | Treasury Stock |    |   | Non-      |   |   |    |   |
|                                                                    |   | Number of          |       |   | Par        |   |   | Paid-In |   |   | Retained |   |   | Comprehensive  |    |   | Number of |   |   |    |   |   | Controlling |   |   | Total  |     |
|                                                                    |   | Shares             |       |   | Value      |   |   | Capital |   |   | Earnings |   |   | Income (Loss)  |    |   | Shares    |   |   | Amount  |   |   | Interest    |   |   | Equity |     |
| BALANCE, December 31, 2007                                              |   |               | 23,080,949 |   |       | $      | 1,300  |    |   | $      | 55,907   |   |   | $              | 50,986  |   |      | $      | 226    |    |   |   | 15,000      |   |   | $      | (1,879   | ) |   | $ | 1,486 |   |   | $ | 108,026 |   |
| Stock options exercised, net of capital taxes                           |   |               | 45,410     |   |       |   | 3      |    |   |   | (1,220   | )      |   |           | (579    | )      |      |   | -      |    |   |   | (40,579     | )      |   |   | 2,964    |   |   |   | - |   |   |   | 1,168 |   |
| Stock-based compensation, net of awards issued                          |   |               | 129,550    |   |       |   | 7      |    |   |   | 4,087    |   |   |           | (1,830  | )      |      |   | -      |    |   |   | (32,850     | )      |   |   | 2,477    |   |   |   | - |   |   |   | 4,741 |   |
| Tax benefit of stock-based awards issued                                |   |               | -          |   |       |   | -      |    |   |   | 11,037   |   |   |           | -       |   |      |   | -      |    |   |   | -           |   |   |   | -        |   |   |   | - |   |   |   | 11,037 |   |
| Repurchases of common shares                                            |   |               | -          |   |       |   | -      |    |   |   | -        |   |   |           | -       |   |      |   | -      |    |   |   | 294,305     |   |   |   | (31,740  | ) |   |   | - |   |   |   | (31,740 | ) |
| Cancellation of common shares                                           |   |               | (1,655,000 | )      |       |   | (104   | )       |   |   | (70,921  | )      |   |           | (49,209 | )      |      |   | -      |    |   |   | (1,655,000  | )      |   |   | 120,234  |   |   |   | - |   |   |   | - |   |
| Dividends paid                                                          |   |               | -          |   |       |   | -      |    |   |   | -        |   |   |           | (27,645 | )      |      |   | -      |    |   |   | -           |   |   |   | -        |   |   |   | - |   |   |   | (27,645 | ) |
| Adjustment to previously reported treasury shares                       |   |               | 3,919,047  |   |       |   | 224    |    |   |   | 58,116   |   |   |           | 279,377 |   |      |   | -      |    |   |   | 3,919,047   |   |   |   | (337,717 | ) |   |   | - |   |   |   | - |   |
| Repurchases of senior exchangeable notes                                |   |               | -          |   |       |   | -      |    |   |   | (3,987   | )      |   |           | -       |   |      |   |   |    |   |   | -           |   |   |   | -        |   |   |   | - |   |   |   | (3,987 | ) |
| Non-controlling interest contributions                                  |   |               | -          |   |       |   | -      |    |   |   | -        |   |   |           | -       |   |      |   | -      |    |   |   | -           |   |   |   | -        |   |   |   | 370 |   |   |   | 370 |   |
| Non-controlling interest dividend                                       |   |               | -          |   |       |   | -      |    |   |   | -        |   |   |           | -       |   |      |   | -      |    |   |   | -           |   |   |   | -        |   |   |   | (40 | ) |   |   | (40 | ) |
| Comprehensive income:                                                   |   |               |       |   |       |   |   |    |   |   |     |   |   |           |    |   |      |   |   |    |   |   |        |   |   |   |     |   |   |   |   |   |   |   |   |   |
| Adjustment of unrecognized pension actuarial loss, net of $1,782 tax    |   |               | -          |   |       |   | -      |    |   |   | -        |   |   |           | -       |   |      |   | (5,207 | )       |   |   | -           |   |   |   | -        |   |   |   | - |   |   |   | (5,207 | ) |
| Amortization of prior service cost and transition asset, net of $18 tax |   |               | -          |   |       |   | -      |    |   |   | -        |   |   |           | -       |   |      |   | 54     |    |   |   | -           |   |   |   | -        |   |   |   | - |   |   |   | 54 |   |
| Net income                                                              |   |               | -          |   |       |   | -      |    |   |   | -        |   |   |           | 131,166 |   |      |   | -      |    |   |   | -           |   |   |   | -        |   |   |   | 342 |   |   |   | 131,508 |   |
| Total comprehensive income                                              |   |               |       |   |       |   |   |    |   |   |     |   |   |           |    |   |      |   |   |    |   |   |        |   |   |   |     |   |   |   |   |   |   |   | 126,355 |   |
|                                                                    |   |               |       |   |       |   |   |    |   |   |     |   |   |           |    |   |      |   |   |    |   |   |        |   |   |   |     |   |   |   |   |   |   |   |   |   |
| BALANCE, December 31, 2008                                              |   |               | 25,519,956 |   |       |   | 1,430  |    |   |   | 53,019   |   |   |           | 382,266 |   |      |   | (4,927 | )  |   |   | 2,499,923   |   |   |   | (245,661 | ) |   |   | 2,158 |   |   |   | 188,285 |   |
| Stock options exercised, net of capital taxes                           |   |               | -          |   |       |   | -      |    |   |   | (1,767   | )      |   |           | -       |   |      |   | -      |    |   |   | (27,650     | )      |   |   | 2,175    |   |   |   | - |   |   |   | 408 |   |
| Stock-based compensation, net of awards issued                          |   |               | -          |   |       |   | -      |    |   |   | (280     | )      |   |           | -       |   |      |   | -      |    |   |   | (78,150     | )      |   |   | 6,176    |   |   |   | - |   |   |   | 5,896 |   |
| Tax benefit of stock-based awards issued                                |   |               | -          |   |       |   | -      |    |   |   | 170      |   |   |           | -       |   |      |   | -      |    |   |   | -           |   |   |   | -        |   |   |   | - |   |   |   | 170 |   |
| Repurchases of common shares                                            |   |               | -          |   |       |   | -      |    |   |   | -        |   |   |           | -       |   |      |   | -      |    |   |   | 139,129     |   |   |   | (9,389   | ) |   |   | - |   |   |   | (9,389 | ) |
| Dividends paid                                                          |   |               | -          |   |       |   | -      |    |   |   | -        |   |   |           | (26,416 | )      |      |   | -      |    |   |   | -           |   |   |   | -        |   |   |   | - |   |   |   | (26,416 | ) |
| Sale of note hedge claim                                                |   |               | -          |   |       |   | -      |    |   |   | 10,577   |   |   |           | -       |   |      |   | -      |    |   |   | -           |   |   |   | -        |   |   |   | - |   |   |   | 10,577 |   |
| Non-controlling interest dividend                                       |   |               | -          |   |       |   | -      |    |   |   | -        |   |   |           | -       |   |      |   | -      |    |   |   | -           |   |   |   | -        |   |   |   | (259 | ) |   |   | (259 | ) |
| Comprehensive income:                                                   |   |               |       |   |       |   |   |    |   |   |     |   |   |           |    |   |      |   |   |    |   |   |        |   |   |   |     |   |   |   |   |   |   |   |   |   |
| Adjustment of unrecognized pension actuarial loss, net of $632 tax      |   |               | -          |   |       |   | -      |    |   |   | -        |   |   |           | -       |   |      |   | (1,845 | )       |   |   | -           |   |   |   | -        |   |   |   | - |   |   |   | (1,845 | ) |
| Amortization of prior service cost and transition asset, net of $81 tax |   |               | -          |   |       |   | -      |    |   |   | -        |   |   |           | -       |   |      |   | 236    |    |   |   | -           |   |   |   | -        |   |   |   | - |   |   |   | 236 |   |
| Net income                                                              |   |               | -          |   |       |   | -      |    |   |   | -        |   |   |           | 113,604 |   |      |   | -      |    |   |   | -           |   |   |   | -        |   |   |   | 491 |   |   |   | 114,095 |   |
| Total comprehensive income                                              |   |               |       |   |       |   |   |    |   |   |     |   |   |           |    |   |      |   |   |    |   |   |        |   |   |   |     |   |   |   |   |   |   |   | 112,486 |   |
|                                                                    |   |               |       |   |       |   |   |    |   |   |     |   |   |           |    |   |      |   |   |    |   |   |        |   |   |   |     |   |   |   |   |   |   |   |   |   |
| BALANCE, December 31, 2009                                              |   |               | 25,519,956 |   |       | $      | 1,430  |    |   | $      | 61,719   |   |   | $              | 469,454 |   |      | $      | (6,536 | )  |   |   | 2,533,252   |   |   | $      | (246,699 | ) |   | $ | 2,390 |   |   | $ | 281,758 |   |

Return to index

----

CONSOLIDATED STATEMENTS OF CASH FLOWS

|                                                                          |   | 2009   |    |   | 2008   |   |     | 2007   |   |
|-------------------------------------------------------------------------------|--------|--------|---------|--------|--------|--------|----------|--------|--------|
| CASH FLOWS FROM OPERATING ACTIVITIES:                                         |   |   |    |   |   |   |     |   |   |
| Net income                                                                    |   | $      | 114,095 |   |   | $      | 131,508  |   |   | $ | 111,315 |   |
| Adjustments to reconcile income to net cash provided by operating activities: |   |   |    |   |   |   |     |   |   |   |   |   |
| Net provision for (recoveries of) doubtful accounts                           |   |   | 545     |   |   |   | (233     | )      |   |   | 262 |   |
| Provision for inventory obsolescence                                          |   |   | 807     |   |   |   | 101      |   |   |   | 231 |   |
| Equity in (earnings) loss of affiliates                                       |   |   | (92     | )      |   |   | (300     | )      |   |   | 656 |   |
| Stock-based compensation                                                      |   |   | 5,896   |   |   |   | 4,741    |   |   |   | 4,667 |   |
| Depreciation and amortization                                                 |   |   | 23,818  |   |   |   | 21,773   |   |   |   | 19,476 |   |
| Debt issuance costs amortization and finance charges                          |   |   | 144     |   |   |   | 3,970    |   |   |   | 1,721 |   |
| Non-cash interest expense                                                     |   |   | 14,544  |   |   |   | 16,469   |   |   |   | 15,828 |   |
| Loss (gain) on sale of assets                                                 |   |   | 90      |   |   |   | (2,015   | )      |   |   | (10,354 | ) |
| Gain on repurchase of senior exchangeable notes                               |   |   | -       |   |   |   | (2,829   | )      |   |   | - |   |
| Realization of pension obligation                                             |   |   | 364     |   |   |   | 54       |   |   |   | (342 | ) |
| Decrease (increase) in value of life insurance policies                       |   |   | (1,997  | )      |   |   | 3,904    |   |   |   | (731 | ) |
| Deferred income taxes                                                         |   |   | 25,636  |   |   |   | (9,596   | )      |   |   | 166 |   |
| Changes in assets and liabilities, net of effects of acquisitions:            |   |   |    |   |   |   |     |   |   |   |   |   |
| Accounts receivable                                                           |   |   | 9,990   |   |   |   | (5,025   | )      |   |   | (24,721 | ) |
| Inventories                                                                   |   |   | 1,847   |   |   |   | (5,576   | )      |   |   | 1,047 |   |
| Prepaid expenses and other current assets                                     |   |   | (27,762 | )      |   |   | 3,926    |   |   |   | (10,178 | ) |
| Other assets                                                                  |   |   | (1,060  | )      |   |   | 71       |   |   |   | 22 |   |
| Accounts payable                                                              |   |   | (8,579  | )      |   |   | 1,454    |   |   |   | 2,173 |   |
| Accrued expenses                                                              |   |   | 18,813  |   |   |   | (2,649   | )      |   |   | 5,663 |   |
| Other long-term liabilities                                                   |   |   | 4,774   |   |   |   | (4,541   | )      |   |   | 8,794 |   |
| Net cash provided by operating activities                                     |   |   | 181,873 |   |   |   | 155,207  |   |   |   | 125,695 |   |
| CASH FLOWS FROM INVESTING ACTIVITIES:                                         |   |   |    |   |   |   |     |   |   |   |   |   |
| Capital expenditures                                                          |   |   | (17,289 | )      |   |   | (30,950  | )      |   |   | (23,827 | ) |
| Patents and other intangibles                                                 |   |   | (240    | )      |   |   | (354     | )      |   |   | (317 | ) |
| Acquisitions, net of cash acquired                                            |   |   | -       |   |   |   | (11,536  | )      |   |   | (7,338 | ) |
| Non-controlling interest - contribution                                       |   |   | -       |   |   |   | 370      |   |   |   | - |   |
| Proceeds from sale of assets                                                  |   |   | 584     |   |   |   | 3,798    |   |   |   | 13,789 |   |
| Premiums on life insurance                                                    |   |   | (1,595  | )      |   |   | (2,436   | )      |   |   | (2,282 | ) |
| Net cash used in investing activities                                         |   |   | (18,540 | )      |   |   | (41,108  | )      |   |   | (19,975 | ) |
| CASH FLOWS FROM FINANCING ACTIVITIES:                                         |   |   |    |   |   |   |     |   |   |   |   |   |
| Repayment of debt borrowings                                                  |   |   | -       |   |   |   | (61,046  | )      |   |   | (4,246 | ) |
| Proceeds from debt borrowings                                                 |   |   | -       |   |   |   | 5,000    |   |   |   | 4,516 |   |
| Capital lease obligations                                                     |   |   | -       |   |   |   | (351     | )      |   |   | (7 | ) |
| Stock options exercised                                                       |   |   | 408     |   |   |   | 1,167    |   |   |   | 18,454 |   |
| Repurchase of common shares                                                   |   |   | (9,389  | )      |   |   | (31,740  | )      |   |   | (181,812 | ) |
| Proceeds from sale of note hedge claim                                        |   |   | 17,060  |   |   |   | -        |   |   |   | - |   |
| Debt refinancing costs                                                        |   |   | -       |   |   |   | -        |   |   |   | (167 | ) |
| Dividends paid                                                                |   |   | (26,416 | )      |   |   | (27,645  | )      |   |   | - |   |
| Non-controlling interest - dividend                                           |   |   | (259    | )      |   |   | -        |   |   |   | - |   |
| Excess tax benefits from stock-based payments                                 |   |   | 170     |   |   |   | 11,037   |   |   |   | 28,936 |   |
| Net cash used in financing activities                                         |   |   | (18,426 | )      |   |   | (103,578 | )      |   |   | (134,326 | ) |
| NET CHANGE IN CASH AND CASH EQUIVALENTS                                       |   |   | 144,907 |   |   |   | 10,521   |   |   |   | (28,606 | ) |
| CASH AND CASH EQUIVALENTS, beginning of year                                  |   |   | 36,138  |   |   |   | 25,617   |   |   |   | 54,223 |   |
| CASH AND CASH EQUIVALENTS, end of year                                        |   | $      | 181,045 |   |   | $      | 36,138   |   |   | $ | 25,617 |   |
|                                                                          |   |   |    |   |   |   |     |   |   |   |   |   |
| Supplemental disclosures of cash flow information:                            |   |   |    |   |   |   |     |   |   |   |   |   |
| Cash payments for interest                                                    |   | $      | 597     |   |   | $      | 763      |   |   | $ | 738 |   |
| Cash payments for income taxes                                                |   | $      | 41,703  |   |   | $      | 56,081   |   |   | $ | 29,801 |   |
|                                                                          |   |   |    |   |   |   |     |   |   |   |   |   |
| Non-cash investing and financing activities:                                  |   |   |    |   |   |   |     |   |   |   |   |   |
| Financed capital expenditures                                                 |   | $      | 1,810   |   |   | $      | -        |   |   | $ |  - |   |
| Insurance premium financed                                                    |   | $      | -       |   |   | $      | -        |   |   | $ | 3,024 |   |
| Common stock issued related to compensation plans                             |   | $      | 5,896   |   |   | $      | 4,741    |   |   | $ | 4,667 |   |
|                                                                          |   |

Return to index

----

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Return to index

----

| -      | allowance for doubtful accounts;             |
|--------|----------------------------------------------|
|   |                                         |
| -      | inventory reserves;                          |
|   |                                         |
| -      | depreciation and amortization;               |
|   |                                         |
| -      | pensions and other postretirement benefits;  |
|   |                                         |
| -      | stock-based compensation;                    |
|   |                                         |
| -      | income taxes; and                            |
|   |                                         |
| -      | long-lived assets, intangibles and goodwill. |

Return to index

----

| Buildings and leasehold improvements | 3 - 40 years |
|--------------------------------------|--------------|
| Machinery and equipment              | 3 - 10 years |

|                                   |   | 2009   |         |   | 2008   |   |
|----------------------------------------|--------|--------|--------------|--------|--------|--------|
|                                   |   |   |         |   |   |   |
| Cash surrender value of life insurance |   | $      | 11,717       |   |   | $      |  7,614 |   |
| Investments                            |   |   | 319          |   |   |   | 341 |   |
| Debt issuance costs                    |   |   | 144          |   |   |   | 288 |   |
| Other                                  |   |   | 1,545        |   |   |   | 884 |   |
| Total other assets                     |   | $      |  13,725 |   |   | $      | 9,127 |   |

Return to index

----

Return to index

----

|                                                                         | Year Ended December 31, |
|------------------------------------------------------------------------------|-------------------------|
|                                                                         | 2009                    |   | 2008 |   | 2007 |
| Weighted average basic common shares outstanding                        |  22,969            |   |  23,008 |   |  23,537 |
| Effect of dilutive securities:                                               |                    |   |   |   |   |
|   Stock options                                                    | 58                      |   | 130 |   | 333 |
|   Contingent shares                                                | 16                      |   | 25 |   | 95 |
|   Restricted stock and other                                       | 189                     |   | 168 |   | 111 |
|   Senior exchangeable notes                                        | 96                      |   | 613 |   | 332 |
| Weighted average diluted common and potential common shares outstanding |  23,328            |   |  23,944 |   |  24,408 |

Return to index

----

|                |   | 2009   |   |   | 2008   |   |
|---------------------|--------|--------|--------|--------|--------|--------|
|                |   |   |   |   |   |   |
| Finished goods      |   | $      | 22,161 |   |   | $      | 26,785 |   |
| Parts and materials |   |   | 8,756  |   |   |   | 7,190 |   |
| Work in progress    |   |   | 1,267  |   |   |   | 863 |   |
| Total inventories   |   | $      | 32,184 |   |   | $      | 34,838 |   |

|                                             |   | 2009   |     |   | 2008   |   |
|--------------------------------------------------|--------|--------|----------|--------|--------|--------|
|                                             |   |   |     |   |   |   |
| Land                                             |   | $      | 5,829    |   |   | $      | 5,874 |   |
| Building and leasehold improvements              |   |   | 67,887   |   |   |   | 64,593 |   |
| Machinery and equipment                          |   |   | 167,180  |   |   |   | 159,593 |   |
| Total property, plant and equipment              |   |   | 240,896  |   |   |   | 230,060 |   |
| Less - accumulated depreciation and amortization |   |   | (142,112 | )      |   |   | (126,597 | ) |
| Property, plant and equipment, net               |   | $      | 98,784   |   |   | $      | 103,463 |   |

|                            |   |                   |   |   | 2009                |   |   | 2008                    |   |
|---------------------------------|--------|------------------------|--------|--------|---------------------|--------|--------|-------------------------|--------|
|                            |   | Original life in years |   |   | Gross CarryingValue |   |   | AccumulatedAmortization |   |   | Gross CarryingValue |   |   | AccumulatedAmortization |   |
|                            |   |                   |   |   |                |   |   |                    |   |   |   |   |   |   |   |
| Acquired trade secrets          |   |                   | 3-20   |   |                | $      | 1,671  |                    |   | $ | 939 |   |   | $ | 1,669 |   |   | $ | 797 |   |
| Acquired patents and trademarks |   |                   | 10     |   |                |   | 3,165  |                    |   |   | 1,965 |   |   |   | 2,953 |   |   |   | 1,752 |   |
| Agreements not to compete       |   |                   | 3-7    |   |                |   | 1,290  |                    |   |   | 933 |   |   |   | 1,290 |   |   |   | 636 |   |
| Acquired trade names            |   |                   | 30     |   |                |   | 583    |                    |   |   | 244 |   |   |   | 557 |   |   |   | 184 |   |
| Acquired trade names            |   | Indefinite             |   |   |                | 3,892  |   |                    |   | - |   |   |   | 3,892 |   |   |   | - |   |
| Total intangibles               |   |                   |   |   |                | $      | 10,601 |                    |   | $ | 4,081 |   |   | $ | $ 10,361 |   |   | $ | 3,369 |   |

| 2010 |   | $      | 615 |   |
|------|--------|--------|-----|--------|
| 2011 |   |   | 403 |   |
| 2012 |   |   | 331 |   |
| 2013 |   |   | 331 |   |
| 2014 |   |   | 331 |   |

Return to index

----

|                         |   | ReservoirDescription |   |   | Production Enhancement |   |   | ReservoirManagement |   |   | Total |   |
|-----------------------------------|--------|----------------------|--------|--------|------------------------|--------|--------|---------------------|--------|--------|-------|--------|
| Balance at December 31, 2007      |   | $                    | 71,132 |   |                   | $      | 64,823 |                |   | $      | 2,845 |   |   | $ | 138,800 |   |
| Goodwill acquired during the year |   |                 | 9,800  |   |                   |   | -      |                |   |   | -     |   |   |   | 9,800 |   |
| Balance at December 31, 2008      |   |                 | 80,932 |   |                   |   | 64,823 |                |   |   | 2,845 |   |   |   | 148,600 |   |
| Goodwill acquired during the year |   |                 | -      |   |                   |   | -      |                |   |   | -     |   |   |   | - |   |
| Balance at December 31, 2009      |   | $                    | 80,932 |   |                   | $      | 64,823 |                |   | $      | 2,845 |   |   | $ | 148,600 |   |

|                                      |   | December 31, |    |   | December 31, |   |
|-------------------------------------------|--------|--------------|---------|--------|--------------|--------|
|                                      |   | 2009         |    |   | 2008         |   |
|                                      |   |         |    |
| Senior exchangeable notes                 |   | $            | 238,658 |   |         | $      | 238,658 |   |
| Discount on senior exchangeable notes     |   |         | (29,546 | )      |         |   | (44,090 | ) |
|   Net senior exchangeable notes |   | $            | 209,112 |   |         | $      | 194,568 |   |

Return to index

----

|                                       |   | 2009   |    |   | 2008   |   |    | 2007   |   |
|--------------------------------------------|--------|--------|---------|--------|--------|--------|---------|--------|--------|
|                                       |   |   |    |   |   |   |    |   |   |
| United States                              |   | $      | 69,444  |   |   | $      | 73,641  |   |   | $ | 50,466 |   |
| Other countries                            |   |   | 101,815 |   |   |   | 114,633 |   |   |   | 115,106 |   |
| Operating income before income tax expense |   | $      | 171,259 |   |   | $      | 188,274 |   |   | $ | 165,572 |   |

Return to index

----

|                 |   | 2009   |   |   | 2008   |   |   | 2007   |   |
|----------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| Current:             |   |   |   |   |   |   |   |   |   |
| United States        |   | $      | 10,110 |   |   | $      | 35,775 |   |   | $ | 22,831 |   |
| Other countries      |   |   | 18,628 |   |   |   | 24,308 |   |   |   | 26,134 |   |
| State and provincial |   |   | 2,790  |   |   |   | 6,279  |   |   |   | 5,126 |   |
|                 |   |   | 31,528 |   |   |   | 66,362 |   |   |   | 54,091 |   |
| Deferred:            |   |   |   |   |   |   |   |   |   |   |   |   |
| United States        |   |   | 23,031 |   |   |   | (626   | )      |   |   | (336 | ) |
| Other countries      |   |   | 1,441  |   |   |   | (9,514 | )      |   |   | 584 |   |
| State and provincial |   |   | 1,164  |   |   |   | 544    |   |   |   | (82 | ) |
| Total deferred       |   |   | 25,636 |   |   |   | (9,596 | )      |   |   | 166 |   |
| Income tax expense   |   | $      | 57,164 |   |   | $      | 56,766 |   |   | $ | 54,257 |   |

|                                                                           |   | 2009   |   |   | 2008   |   |   | 2007   |   |
|--------------------------------------------------------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
|                                                                           |   |   |   |   |   |   |   |   |   |
| Tax at The Netherlands income tax rate                                         |   | $      | 43,671 |   |   | $      | 48,010 |   |   | $ | 42,221 |   |
| Reserve for pending audit settlement                                           |   |   | (4,468 | )      |   |   | -      |   |   |   | 6,817 |   |
| International earnings taxed at rates other thanThe Netherlands statutory rate |   |   | 8,618  |   |   |   | 1,736  |   |   |   | (803 | ) |
| Non-deductible expenses                                                        |   |   | 3,366  |   |   |   | 2,141  |   |   |   | 2,613 |   |
| Change in valuation allowance                                                  |   |   | 1,564  |   |   |   | 1,385  |   |   |   | 291 |   |
| State and provincial taxes                                                     |   |   | 3,954  |   |   |   | 6,823  |   |   |   | 5,043 |   |
| Other                                                                          |   |   | 459    |   |   |   | (3,329 | )      |   |   | (1,925 | ) |
| Income tax expense                                                             |   | $      | 57,164 |   |   | $      | 56,766 |   |   | $ | 54,257 |   |

|                                                      |   | 2009   |    |   | 2008   |   |
|-----------------------------------------------------------|--------|--------|---------|--------|--------|--------|
| Deferred tax assets:                                      |   |   |    |   |   |   |
| Net operating loss carry-forwards                         |   | $      | 9,811   |   |   | $      | 10,017 |   |
| Tax credit carry-forwards                                 |   |   | 8,726   |   |   |   | 9,853 |   |
| Reserves                                                  |   |   | 12,391  |   |   |   | 11,360 |   |
| Unrealized benefit plan loss                              |   |   | 1,309   |   |   |   | 1,760 |   |
| Other                                                     |   |   | 1,406   |   |   |   | 2,822 |   |
|                                                      |   |   | 33,643  |   |   |   | 35,812 |   |
| Valuation allowance                                       |   |   | (10,664 | )      |   |   | (9,415 | ) |
| Net deferred tax asset                                    |   |   | 22,979  |   |   |   | 26,397 |   |
| Deferred tax liabilities:                                 |   |   |    |   |   |   |   |   |
| Intangibles                                               |   |   | (227    | )      |   |   | (1,917 | ) |
| Property, plant and equipment                             |   |   | 3,001   |   |   |   | (574 | ) |
| Convertible debt                                          |   |   | (28,249 | )      |   |   | - |   |
| Other                                                     |   |   | (250    | )      |   |   | (3,147 | ) |
| Total deferred tax liabilities                            |   |   | (25,725 | )      |   |   | (5,638 | ) |
| Net deferred income taxes                                 |   | $      | (2,746  | )      |   | $      | 20,759 |   |
|                                                      |   |   |    |   |   |   |   |   |
|                                                      |   |   | 2009    |   |   |   | 2008 |   |
|                                                      |   |   |    |   |   |   |   |   |
| Current deferred tax assets                               |   | $      | 4,946   |   |   | $      | 3,051 |   |
| Long-term deferred tax (liabilities) assets               |   |   | (7,692  | )      |   |   | 17,708 |   |
|    Total deferred tax (liabilities) assets |   | $      | (2,746  | )      |   | $      | 20,759 |   |

Return to index

----

|                                                  |   | 2009   |   |   | 2008   |   |         | 2007   |   |
|-------------------------------------------------------|--------|--------|--------|--------|--------|--------|--------------|--------|--------|
|                                                  |   |   |   |   |   |   |         |   |   |
| Unrecognized tax benefits at January 1,               |   | $      | 5,974  |   |   | $      |  17,864 |   |   | $ | 13,064 |   |
| Tax positions, current period                         |   |   | 4,668  |   |   |   | 1,001        |   |   |   | 298 |   |
| Tax positions, prior period                           |   |   | -      |   |   |   | -            |   |   |   | 4,584 |   |
| Settlements with taxing authorities                   |   |   | (1,449 | )      |   |   | (12,603      | )      |   |   | (75 | ) |
| Lapse of applicable statute of limitations            |   |   | (869   | )      |   |   | (288         | )      |   |   | (7 | ) |
|   Unrecognized tax benefits at December 31, |   | $      | 8,324  |   |   | $      | 5,974        |   |   | $ | 17,864 |   |

Return to index

----

|                                                      |   | 2009   |   |   | 2008   |   |
|-----------------------------------------------------------|--------|--------|--------|--------|--------|--------|
| Projected Benefit Obligation:                             |   |   |   |   |   |   |
| Projected benefit obligation at beginning of year         |   | $      | 24,610 |   |   | $      | 24,352 |   |
| Service cost                                              |   |   | 1,084  |   |   |   | 1,139 |   |
| Interest cost                                             |   |   | 1,386  |   |   |   | 1,342 |   |
| Benefits paid                                             |   |   | (484   | )      |   |   | (499 | ) |
| Administrative expenses                                   |   |   | (276   | )      |   |   | (247 | ) |
| Actuarial loss (gain), net                                |   |   | 2,710  |   |   |   | (306 | ) |
| Unrealized (gain) loss on foreign exchange                |   |   | 669    |   |   |   | (1,171 | ) |
| Projected benefit obligation at end of year               |   | $      | 29,699 |   |   | $      | 24,610 |   |
|                                                      |   |   |   |   |   |   |   |   |
| Fair Value of Plan Assets:                                |   |   |   |   |   |   |   |   |
| Fair value of plan assets at beginning of year            |   | $      | 21,187 |   |   | $      | 27,136 |   |
| Actual (loss) gain on plan assets                         |   |   | 907    |   |   |   | (6,502 | ) |
| Employer contributions                                    |   |   | 2,713  |   |   |   | 2,231 |   |
| Benefits paid                                             |   |   | (484   | )      |   |   | (499 | ) |
| Administrative expenses                                   |   |   | (276   | )      |   |   | (247 | ) |
| Unrealized (loss) gain on foreign exchange                |   |   | 593    |   |   |   | (932 | ) |
| Fair value of plan assets at end of year                  |   | $      | 24,640 |   |   | $      | 21,187 |   |
|                                                      |   |   |   |   |   |   |   |   |
| Over (under)-funded status of the plan at end of the year |   | $      | (5,059 | )      |   | $      | (3,423 | ) |
|                                                      |   |   |   |   |   |   |   |   |
| Accumulated Benefit Obligation                            |   | $      | 24,599 |   |   | $      | 20,150 |   |

|                                           | 2009  |   | 2008  |
|------------------------------------------------|-------|--------|-------|
| Weighted average assumed discount rate         | 5.25% |   | 5.75% |
| Weighted average rate of compensation increase | 3.00% |   | 3.00% |

|                                          |   | 2009   |   |   | 2008   |   |
|-----------------------------------------------|--------|--------|--------|--------|--------|--------|
|                                          |   |   |   |   |   |   |
| Deferred tax asset                            |   | $      | 1,309  |   |   | $      | 1,760 |   |
| Other long-term liabilities                   |   |   | 5,059  |   |   |   | 3,423 |   |
| Accumulated other comprehensive income (loss) |   |   | (6,536 | )      |   |   | (4,927 | ) |

Return to index

----

|                                                                  |   | 2009   |   |   | 2008   |   |
|-----------------------------------------------------------------------|--------|--------|--------|--------|--------|--------|
| Prior service cost                                                    |   | $      | (971   | )      |   | $      | (1,089 | ) |
| Transition asset                                                      |   |   | 389    |   |   |   | 454 |   |
| Unrecognized net actuarial gain (loss) and foreign exchange           |   |   | (5,954 | )      |   |   | (4,292 | ) |
|    Total accumulated other comprehensive income (loss) |   | $      | (6,536 | )      |   | $      | (4,927 | ) |

|                                         |   | 2009   |   |   | 2008   |   |
|----------------------------------------------|--------|--------|--------|--------|--------|--------|
| Service cost                                 |   | $      | 1,084  |   |   | $      | 1,139 |   |
| Interest cost                                |   |   | 1,386  |   |   |   | 1,342 |   |
| Expected return on plan assets               |   |   | (673   | )      |   |   | (1,218 | ) |
| Unrecognized pension obligation (asset), net |   |   | (87    | )      |   |   | (97 | ) |
| Prior service cost                           |   |   | 159    |   |   |   | 178 |   |
| Unrecognized net actuarial (gain)/ loss      |   |   | 243    |   |   |   | - |   |
|    Net periodic pension cost  |   | $      | 2,112  |   |   | $      | 1,344 |   |

|                                             | 2009  |   | 2008  |
|--------------------------------------------------|-------|--------|-------|
| Weighted average assumed discount rate           | 5.75% |   | 5.50% |
| Expected long-term rate of return on plan assets | 5.75% |   | 4.25% |
| Weighted average rate of compensation increase   | 3.00% |   | 3.00% |

| 2010                  |   | $      | 551   |   |
|-----------------------|--------|--------|-------|--------|
| 2011                  |   |   | 640   |   |
| 2012                  |   |   | 1,040 |   |
| 2013                  |   |   | 1,143 |   |
| 2014                  |   |   | 1,246 |   |
| Succeeding five years |   |   | 7,640 |   |

Return to index

----

|                                                      |   |   |   |   | Fair Value Measurement at December 31, 2009 |   |
|-----------------------------------------------------------|--------|--------|--------|--------|---------------------------------------------|--------|
|                                                      |   | Total  |   |   | Level 1                                     |   |   | Level 2 |   |   | Level 3 |   |
| Assets:                                                   |   |   |   |   |                                        |   |   |   |   |   |   |   |
|    Deferred compensation plan trust assets |   | $      | 6,193  |   |                                        | $      | - |   |   | $ | 6,193 |   |   | $ | - |   |
|                                                      |   |   |   |   |                                        |   |   |   |   |   |   |   |   |   |   |   |
| Liabilities:                                              |   |   |   |   |                                        |   |   |   |   |   |   |   |   |   |   |   |
|    Deferred compensation plan              |   | $      | 9,366  |   |                                        | $      | 1,339 |   |   | $ | 8,027 |   |   | $ | - |   |

|                                                      |   |   |   |   | Fair Value Measurement at December 31, 2008 |   |
|-----------------------------------------------------------|--------|--------|--------|--------|---------------------------------------------|--------|
|                                                      |   | Total  |   |   | Level 1                                     |   |   | Level 2 |   |   | Level 3 |   |
| Assets:                                                   |   |   |   |   |                                        |   |   |   |   |   |   |   |
|    Deferred compensation plan trust assets |   | $      | 3,622  |   |                                        | $      | - |   |   | $ | 3,622 |   |   | $ | - |   |
|                                                      |   |   |   |   |                                        |   |   |   |   |   |   |   |   |   |   |   |
| Liabilities:                                              |   |   |   |   |                                        |   |   |   |   |   |   |   |   |   |   |   |
|    Deferred compensation plan              |   | $      | 5,746  |   |                                        | $      | 478 |   |   | $ | 5,268 |   |   | $ | - |   |

Return to index

----

| 2010              |   | $      | 6,682  |   |
|-------------------|--------|--------|--------|--------|
| 2011              |   |   | 4,771  |   |
| 2012              |   |   | 4,038  |   |
| 2013              |   |   | 2,799  |   |
| 2014              |   |   | 1,907  |   |
| Thereafter        |   |   | 3,733  |   |
| Total commitments |   | $      | 23,930 |   |

Return to index

----

Return to index

----

Return to index

----

|                           |   | Number of Shares |    |   | Weighted Average Grant Date Fair Value |   |
|--------------------------------|--------|------------------|---------|--------|----------------------------------------|--------|
| Nonvested at December 31, 2008 |   |             | 330,702 |   |                                   | $      | 90.49 |   |
| Granted                        |   |             | 130,492 |   |                                   |   | 87.57 |   |
| Vested                         |   |             | (78,150 | )      |                                   |   | 82.21 |   |
| Forfeited                      |   |             | (8,300  | )      |                                   |   | 97.64 |   |
| Nonvested at December 31, 2009 |   |             | 374,744 |   |                                   | $      | 91.05 |   |

|                                |   | Shares |    |   | Range of Exercise Prices |   |                   | Weighted Average Exercise Price |   |   | Weighted Average Remaining Life |   |   | Average Intrinsic Value - Per Share |   |
|-------------------------------------|--------|--------|---------|--------|--------------------------|--------|------------------------|---------------------------------|--------|--------|---------------------------------|--------|--------|-------------------------------------|--------|
| Balance as of December 31, 2008     |   |   | 120,951 |   |                     | $      | 0.01 - 25.00 |                            |   | $      | 9.58                            |   |   |                                | 2.5    |   |   | $ | 50.28 |   |
|    Options granted   |   |   | -       |   |                     |   | -                      |                            |   |   | -                               |   |   |                                |   |   |   |   |   |   |
|    Options exercised |   |   | (27,650 | )      |                     |   | 10.26 - 25.00          |                            |   |   | 14.77                           |   |   |                                |   |   |   |   |   |   |
|    Options forfeited |   |   | (41,465 | )      |                     |   | 0.01                   |                            |   |   | 0.01                            |   |   |                                |   |   |   |   |   |   |
| Balance as of December 31, 2009     |   |   | 51,836  |   |                     | $      | 8.84 - 25.00 |                            |   | $      | 14.48                           |   |   |                                | 1.7    |   |   | $ | 103.64 |   |

|                                               |   |   |   |   |   |   |   |   |   |
|----------------------------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
|                                               |   | 2009   |   |   | 2008   |   |   | 2007   |   |
|                                               |   |   |   |   |   |   |   |   |   |
| Cost of sales and services                         |   | $      | 3,868  |   |   | $      | 2,986  |   |   | $ | 2,256 |   |
| General and administrative                         |   |   | 2,028  |   |   |   | 1,755  |   |   |   | 2,411 |   |
|   Total stock-based compensation expense |   | $      | 5,896  |   |   | $      | 4,741  |   |   | $ | 4,667 |   |

Return to index

----

|                                  |   | Year Ended December 31, |   |
|---------------------------------------|--------|-------------------------|--------|
|                                  |   | 2009                    |   |   | 2008 |   |   | 2007 |   |
|                                  |   |                    |   |   |   |   |   |   |   |
| Loss (gain) on sale of assets         |   | $                       | 90     |   |   | $ | (2,015 | ) |   | $ | (10,354 | ) |
| Equity in (income) loss of affiliates |   |                    | (92    | ) |   |   | (300 | ) |   |   | 656 |   |
| Foreign exchange (gain) loss          |   |                    | (331   | ) |   |   | 6,555 |   |   |   | (1,413 | ) |
| Interest income                       |   |                    | (138   | ) |   |   | (848 | ) |   |   | (1,282 | ) |
| Non-income tax expense (benefit)      |   |                    | (2,500 | ) |   |   | 5,030 |   |   |   | - |   |
| Other                                 |   |                    | (231   | ) |   |   | (2,842 | ) |   |   | (3,522 | ) |
| Total other (income) expense, net     |   | $                       | (3,202 | ) |   | $ | 5,580 |   |   | $ | (15,915 | ) |

|                       |   | Year Ended December 31, |   |
|----------------------------|--------|-------------------------|--------|
| Losses (gains) by currency |   | 2009                    |   |   | 2008 |   |   | 2007 |   |
|                       |   |                    |   |   |   |   |   |   |   |
| Australian Dollar          |   | $                       | (438   | ) |   | $ | 654 |   |   | $ | (15 | ) |
| British Pound              |   |                    | (106   | ) |   |   | 654 |   |   |   | 48 |   |
| Canadian Dollar            |   |                    | (1,686 | ) |   |   | 2,706 |   |   |   | (637 | ) |
| Euro                       |   |                    | (81    | ) |   |   | (132 | ) |   |   | (374 | ) |
| Mexican Peso               |   |                    | (99    | ) |   |   | 683 |   |   |   | 73 |   |
| Russian Ruble              |   |                    | 421    |   |   |   | 688 |   |   |   | (562 | ) |
| Venezuelan Bolivar         |   |                    | 1,335  |   |   |   | (2 | ) |   |   | 6 |   |
| Other currencies           |   |                    | 323    |   |   |   | 1,304 |   |   |   | 48 |   |
| Total losses (gains)       |   | $                       | (331   | ) |   | $ | 6,555 |   |   | $ | (1,413 | ) |

Return to index

----

| -      | Reservoir Description: Encompasses the characterization of petroleum reservoir rock, fluid and gas samples. We provide analytical and field services to characterize properties of crude oil and petroleum products to the oil and gas industry.                                                                            |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                        |
| -      | Production Enhancement: Includes products and services relating to reservoir well completions, perforations, stimulations and production. We provide integrated services to evaluate the effectiveness of well completions and to develop solutions aimed at increasing the effectiveness ofenhanced oil recovery projects. |
|   |                                                                                                                                                                                                                                                                                                                        |
| -      | Reservoir Management: Combines and integrates information from reservoir description and production enhancement services to increase production and improve recovery of oil and gas from our clients' reservoirs.                                                                                                           |

|                                                                                                                     |   | Reservoir Description |    |   | Production Enhancement |   |    | Reservoir Management |   |   | Corporate & Other (1) |   |   | Consolidated |    |
|--------------------------------------------------------------------------------------------------------------------------|--------|-----------------------|---------|--------|------------------------|--------|---------|----------------------|--------|--------|---------------------------|--------|--------|--------------|---------|
| DECEMBER 31, 2009                                                                                                        |   |                  |    |   |                   |   |    |                 |   |   |                      |   |   |         |    |
| Revenues from unaffiliated customers                                                                                     |   | $                     | 414,934 |   |                   | $      | 230,652 |                 |   | $      | 49,953                    |   |   | $            | -       |   |   | $ | 695,539 |   |
| Inter-segment revenues                                                                                                   |   |                  | 1,076   |   |                   |   | 1,424   |                 |   |   | 1,866                     |   |   |         | (4,366  | ) |   |   | - |   |
| Segment income                                                                                                           |   |                  | 106,421 |   |                   |   | 65,076  |                 |   |   | 14,620                    |   |   |         | 665     |   |   |   | 186,782 |   |
| Total assets                                                                                                             |   |                  | 251,671 |   |                   |   | 173,117 |                 |   |   | 25,073                    |   |   |         | 208,305 |   |   |   | 658,166 |   |
| Capital expenditures                                                                                                     |   |                  | 12,311  |   |                   |   | 3,383   |                 |   |   | 247                       |   |   |         | 1,348   |   |   |   | 17,289 |   |
| Depreciation and amortization                                                                                            |   |                  | 14,334  |   |                   |   | 5,858   |                 |   |   | 700                       |   |   |         | 2,926   |   |   |   | 23,818 |   |
|                                                                                                                     |   |                  |    |   |                   |   |    |                 |   |   |                      |   |   |         |    |   |   |   |   |   |
| DECEMBER 31, 2008                                                                                                        |   |                  |    |   |                   |   |    |                 |   |   |                      |   |   |         |    |   |   |   |   |   |
| Revenues from unaffiliated customers                                                                                     |   | $                     | 435,425 |   |                   | $      | 293,017 |                 |   | $      | 52,394                    |   |   | $            | -       |   |   | $ | 780,836 |   |
| Inter-segment revenues                                                                                                   |   |                  | 864     |   |                   |   | 1,096   |                 |   |   | 1,664                     |   |   |         | (3,624  | ) |   |   | - |   |
| Segment income (loss)                                                                                                    |   |                  | 101,783 |   |                   |   | 93,025  |                 |   |   | 16,224                    |   |   |         | (3,977  | ) |   |   | 207,055 |   |
| Total assets                                                                                                             |   |                  | 244,913 |   |                   |   | 181,476 |                 |   |   | 21,195                    |   |   |         | 73,951  |   |   |   | 521,535 |   |
| Capital expenditures                                                                                                     |   |                  | 19,766  |   |                   |   | 8,711   |                 |   |   | 665                       |   |   |         | 1,808   |   |   |   | 30,950 |   |
| Depreciation and amortization                                                                                            |   |                  | 12,639  |   |                   |   | 5,562   |                 |   |   | 619                       |   |   |         | 2,953   |   |   |   | 21,773 |   |
|                                                                                                                     |   |                  |    |   |                   |   |    |                 |   |   |                      |   |   |         |    |   |   |   |   |   |
| DECEMBER 31, 2007                                                                                                        |   |                  |    |   |                   |   |    |                 |   |   |                      |   |   |         |    |   |   |   |   |   |
| Revenues from unaffiliated customers                                                                                     |   | $                     | 374,455 |   |                   | $      | 244,830 |                 |   | $      | 51,255                    |   |   | $            | -       |   |   | $ | 670,540 |   |
| Inter-segment revenues                                                                                                   |   |                  | 968     |   |                   |   | 1,132   |                 |   |   | 1,533                     |   |   |         | (3,633  | ) |   |   | - |   |
| Segment income (loss)                                                                                                    |   |                  | 99,950  |   |                   |   | 68,917  |                 |   |   | 14,650                    |   |   |         | 434     |   |   |   | 183,951 |   |
| Total assets                                                                                                             |   |                  | 213,140 |   |                   |   | 162,864 |                 |   |   | 21,392                    |   |   |         | 79,358  |   |   |   | 476,754 |   |
| Capital expenditures                                                                                                     |   |                  | 15,693  |   |                   |   | 6,208   |                 |   |   | 908                       |   |   |         | 1,018   |   |   |   | 23,827 |   |
| Depreciation and amortization                                                                                            |   |                  | 10,430  |   |                   |   | 5,126   |                 |   |   | 501                       |   |   |         | 3,419   |   |   |   | 19,476 |   |
|                                                                                                                     |   |                  |    |   |                   |   |    |                 |   |   |                      |   |   |         |    |   |   |   |   |   |
| (1)"Corporate and other" represents those items that are not directly relating to a particular segment and eliminations. |   |

Return to index

----

| GEOGRAPHIC INFORMATION  |   | United States |    |   | Canada |   |   | Other Countries |   |   | Consolidated |   |
|------------------------------|--------|---------------|---------|--------|--------|--------|--------|-----------------|--------|--------|--------------|--------|
| DECEMBER 31, 2009            |   |          |    |   |   |   |   |            |   |   |         |   |
| Revenues                     |   | $             | 339,235 |   |   | $      | 54,888 |            |   | $      | 301,416      |   |   | $ | 695,539 |   |
| Operating income             |   |          | 112,158 |   |   |   | 14,430 |            |   |   | 60,194       |   |   |   | 186,782 |   |
| Total assets                 |   |          | 326,223 |   |   |   | 45,344 |            |   |   | 286,599      |   |   |   | 658,166 |   |
|                         |   |          |    |   |   |   |   |            |   |   |         |   |   |   |   |   |
| DECEMBER 31, 2008            |   |          |    |   |   |   |   |            |   |   |         |   |   |   |   |   |
| Revenues                     |   | $             | 391,519 |   |   | $      | 80,449 |            |   | $      | 308,868      |   |   | $ | 780,836 |   |
| Operating income             |   |          | 122,064 |   |   |   | 35,066 |            |   |   | 49,925       |   |   |   | 207,055 |   |
| Total assets                 |   |          | 237,240 |   |   |   | 46,221 |            |   |   | 238,074      |   |   |   | 521,535 |   |
|                         |   |          |    |   |   |   |   |            |   |   |         |   |   |   |   |   |
| DECEMBER 31, 2007            |   |          |    |   |   |   |   |            |   |   |         |   |   |   |   |   |
| Revenues                     |   | $             | 328,073 |   |   | $      | 72,647 |            |   | $      | 269,820      |   |   | $ | 670,540 |   |
| Operating income             |   |          | 96,218  |   |   |   | 31,030 |            |   |   | 56,703       |   |   |   | 183,951 |   |
| Total assets                 |   |          | 213,596 |   |   |   | 43,765 |            |   |   | 219,393      |   |   |   | 476,754 |   |
|                         |   |          |    |   |   |   |   |            |   |   |         |   |   |   |   |   |

Return to index

----

| Condensed Consolidating Balance Sheets            |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |               |       |
|---------------------------------------------------|--------|--------------------------------------------|---------|--------|-------------------------------|--------|---------|--------------------------------------|--------|--------|---------------------------|--------|--------|--------------------|------------|
|                                              |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |               |       |
| (In thousands)                                    |   | December 31, 2009                          |    |
|                                              |   | Core Laboratories N.V. (Parent/ Guarantor) |    |   | Core Laboratories LP (Issuer) |   |    | Other Subsidiaries (Non- Guarantors) |   |   | Consolidating Adjustments |   |   | Consolidated Total |       |
| ASSETS                                            |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |               |       |
| CURRENT ASSETS:                                   |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |               |       |
| Cash and cash equivalents                         |   | $                                          | 73,998  |   |                          | $      | 95,048  |                                 |   | $      | 11,999                    |   |   | $                  | -          |   |   | $ | 181,045 |   |
| Accounts receivable, net                          |   |                                       | 1       |   |                          |   | 29,452  |                                 |   |   | 104,305                   |   |   |               | -          |   |   |   | 133,758 |   |
| Inventories, net                                  |   |                                       | -       |   |                          |   | 2,679   |                                 |   |   | 29,505                    |   |   |               | -          |   |   |   | 32,184 |   |
| Prepaid expenses and other current assets         |   |                                       | 11,809  |   |                          |   | 22,209  |                                 |   |   | 9,532                     |   |   |               | -          |   |   |   | 43,550 |   |
| Total current assets                              |   |                                       | 85,808  |   |                          |   | 149,388 |                                 |   |   | 155,341                   |   |   |               | -          |   |   |   | 390,537 |   |
|                                              |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |               |       |   |   |   |   |   |
| PROPERTY, PLANT AND EQUIPMENT, net                |   |                                       | -       |   |                          |   | 21,988  |                                 |   |   | 76,796                    |   |   |               | -          |   |   |   | 98,784 |   |
| GOODWILL AND INTANGIBLES, net                     |   |                                       | 46,986  |   |                          |   | 7,949   |                                 |   |   | 100,185                   |   |   |               | -          |   |   |   | 155,120 |   |
| INTERCOMPANY RECEIVABLES                          |   |                                       | 37,681  |   |                          |   | 216,670 |                                 |   |   | 232,802                   |   |   |               | (487,153   | ) |   |   | - |   |
| INVESTMENT IN AFFILIATES                          |   |                                       | 540,724 |   |                          |   | -       |                                 |   |   | 1,387,715                 |   |   |               | (1,928,118 | ) |   |   | 321 |   |
| DEFERRED TAX ASSET                                |   |                                       | 2,951   |   |                          |   | 4,644   |                                 |   |   | 14,359                    |   |   |               | (21,954    | ) |   |   | - |   |
| OTHER ASSETS                                      |   |                                       | 2,828   |   |                          |   | 8,770   |                                 |   |   | 1,806                     |   |   |               | -          |   |   |   | 13,404 |   |
| TOTAL ASSETS                                      |   | $                                          | 716,978 |   |                          | $      | 409,409 |                                 |   | $      | 1,969,004                 |   |   | $                  | (2,437,225 | ) |   | $ | 658,166 |   |
|                                              |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |               |       |   |   |   |   |   |
| LIABILITIES AND EQUITY                            |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |               |       |   |   |
| CURRENT LIABILITIES:                              |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |               |       |   |   |   |   |   |
| Accounts payable                                  |   | $                                          | 501     |   |                          | $      | 6,404   |                                 |   | $      | 26,104                    |   |   | $                  | -          |   |   | $ | 33,009 |   |
| Other accrued expenses                            |   |                                       | 673     |   |                          |   | 29,738  |                                 |   |   | 42,988                    |   |   |               | -          |   |   |   | 73,399 |   |
| Total current liabilities                         |   |                                       | 1,174   |   |                          |   | 36,142  |                                 |   |   | 69,092                    |   |   |               | -          |   |   |   | 106,408 |   |
|                                              |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |               |       |   |   |   |   |   |
| LONG-TERM DEBT AND CAPITAL LEASE OBLIGATIONS |   |                                       | -       |   |                          |   | 209,112 |                                 |   |   | -                         |   |   |               | -          |   |   |   | 209,112 |   |
| DEFERRED COMPENSATION                             |   |                                       | 6,046   |   |                          |   | 10,094  |                                 |   |   | 726                       |   |   |               | -          |   |   |   | 16,866 |   |
| DEFERRED TAX LIABILITY                            |   |                                       | -       |   |                          |   | 29,646  |                                 |   |   | -                         |   |   |               | (21,954    | ) |   |   | 7,692 |   |
| INTERCOMPANY PAYABLES                             |   |                                       | 417,618 |   |                          |   | -       |                                 |   |   | 69,535                    |   |   |               | (487,153   | ) |   |   | - |   |
| OTHER LONG-TERM LIABILITIES                       |   |                                       | 12,772  |   |                          |   | 7,702   |                                 |   |   | 15,856                    |   |   |               | -          |   |   |   | 36,330 |   |
|                                              |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |               |       |   |   |   |   |   |
| SHAREHOLDERS' EQUITY                              |   |                                       | 279,368 |   |                          |   | 116,713 |                                 |   |   | 1,811,405                 |   |   |               | (1,928,118 | ) |   |   | 279,368 |   |
| NON-CONTROLLING INTEREST                          |   |                                       | -       |   |                          |   | -       |                                 |   |   | 2,390                     |   |   |               | -          |   |   |   | 2,390 |   |
| TOTAL EQUITY                                      |   |                                       | 279,368 |   |                          |   | 116,713 |                                 |   |   | 1,813,795                 |   |   |               | (1,928,118 | ) |   |   | 281,758 |   |
|                                              |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |               |       |   |   |   |   |   |
| TOTAL LIABILITIES AND EQUITY                      |   | $                                          | 716,978 |   |                          | $      | 409,409 |                                 |   | $      | 1,969,004                 |   |   | $                  | (2,437,225 | ) |   | $ | 658,166 |   |

Return to index

----

| Condensed Consolidating Statements of Operations    |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |
|-----------------------------------------------------|--------|--------------------------------------------|---------|--------|-------------------------------|--------|---------|--------------------------------------|--------|--------|---------------------------|--------|--------|
|                                                |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |   |   |
| (In thousands)                                      |   | Year Ended December 31, 2009               |    |
|                                                |   | Core Laboratories N.V. (Parent/ Guarantor) |    |   | Core Laboratories LP (Issuer) |   |    | Other Subsidiaries (Non- Guarantors) |   |   | Consolidating Adjustments |   |   | Consolidated Total |   |
| REVENUES                                            |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |   |   |
| Operating revenues                                  |   | $                                          | -       |   |                          | $      | 166,295 |                                 |   | $      | 529,244                   |   |   | $ | - |   |   | $ | 695,539 |   |
| Intercompany revenues                               |   |                                       | 1,471   |   |                          |   | 24,611  |                                 |   |   | 114,421                   |   |   |   | (140,503 | ) |   |   | - |   |
| Earnings from consolidated affiliates               |   |                                       | 104,578 |   |                          |   | -       |                                 |   |   | 246,011                   |   |   |   | (350,589 | ) |   |   | - |   |
| Total revenues                                      |   |                                       | 106,049 |   |                          |   | 190,906 |                                 |   |   | 889,676                   |   |   |   | (491,092 | ) |   |   | 695,539 |   |
|                                                |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |   |   |   |   |   |   |   |
| OPERATING EXPENSES                                  |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |   |   |   |   |   |   |   |
| Operating costs                                     |   |                                       | 1,603   |   |                          |   | 90,950  |                                 |   |   | 365,216                   |   |   |   | - |   |   |   | 457,769 |   |
| General and administrative expenses                 |   |                                       | 6,787   |   |                          |   | 23,572  |                                 |   |   | 13                        |   |   |   | - |   |   |   | 30,372 |   |
| Depreciation and amortization                       |   |                                       | -       |   |                          |   | 5,526   |                                 |   |   | 18,292                    |   |   |   | - |   |   |   | 23,818 |   |
| Other expense (income), net                         |   |                                       | (17,491 | )      |                          |   | 4,394   |                                 |   |   | 137,207                   |   |   |   | (127,312 | ) |   |   | (3,202 | ) |
|                                                |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |   |   |   |   |   |   |   |
| Operating income                                    |   |                                       | 115,150 |   |                          |   | 66,464  |                                 |   |   | 368,948                   |   |   |   | (363,780 | ) |   |   | 186,782 |   |
| Gain on repurchase of senior exchangeable notes     |   |                                       | -       |   |                          |   | -       |                                 |   |   | -                         |   |   |   | - |   |   |   | - |   |
| Interest expense                                    |   |                                       | 7       |   |                          |   | 15,481  |                                 |   |   | 35                        |   |   |   | - |   |   |   | 15,523 |   |
|                                                |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |   |   |   |   |   |   |   |
| Income before income tax expense                    |   |                                       | 115,143 |   |                          |   | 50,983  |                                 |   |   | 368,913                   |   |   |   | (363,780 | ) |   |   | 171,259 |   |
| Income tax expense (benefit)                        |   |                                       | 1,539   |   |                          |   | 31,489  |                                 |   |   | 24,136                    |   |   |   | - |   |   |   | 57,164 |   |
|                                                |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |   |   |   |   |   |   |   |
| Net income                                          |   |                                       | 113,604 |   |                          |   | 19,494  |                                 |   |   | 344,777                   |   |   |   | (363,780 | ) |   |   | 114,095 |   |
| Net income attributable to non-controlling interest |   |                                       | -       |   |                          |   | -       |                                 |   |   | 491                       |   |   |   | - |   |   |   | 491 |   |
| Net income attributable to Core Laboratories N.V.   |   | $                                          | 113,604 |   |                          | $      | 19,494  |                                 |   | $      | 344,286                   |   |   | $ | (363,780 | ) |   | $ | 113,604 |   |

| Condensed Consolidating Statements of Cash Flows |   |                                       |    |   |                          |   |   |                                 |   |   |                      |   |   |
|--------------------------------------------------|--------|--------------------------------------------|---------|--------|-------------------------------|--------|--------|--------------------------------------|--------|--------|---------------------------|--------|--------|
|                                             |   |                                       |    |   |                          |   |   |                                 |   |   |                      |   |   |   |   |
| (In thousands)                                   |   | Year Ended December 31, 2009               |    |
|                                             |   | Core Laboratories N.V. (Parent/ Guarantor) |    |   | Core Laboratories LP (Issuer) |   |   | Other Subsidiaries (Non- Guarantors) |   |   | Consolidating Adjustments |   |   | Consolidated Total |   |
|                                             |   |                                       |    |   |                          |   |   |                                 |   |   |                      |   |   |   |   |
| Net cash provided by operating activities        |   | $                                          | 78,818  |   |                          | $      | 88,940 |                                 |   | $      | 14,115                    |   |   | $ | - |   |   | $ | 181,873 |   |
|                                             |   |                                       |    |   |                          |   |   |                                 |   |   |                      |   |   |   | - |   |   |   |   |   |
| CASH FLOWS FROM INVESTING ACTIVITIES:            |   |                                       |    |   |                          |   |   |                                 |   |   |                      |   |   |   |   |   |   |
| Capital expenditures                             |   |                                       | -       |   |                          |   | (3,501 | )                                    |   |   | (13,788                   | )      |   |   | - |   |   |   | (17,289 | ) |
| Patents and other intangibles                    |   |                                       | -       |   |                          |   | (20    | )                                    |   |   | (220                      | )      |   |   | - |   |   |   | (240 | ) |
| Proceeds from sale of assets                     |   |                                       | -       |   |                          |   | 197    |                                 |   |   | 387                       |   |   |   | - |   |   |   | 584 |   |
| Premiums on life insurance                       |   |                                       | -       |   |                          |   | (1,595 | )                                    |   |   | -                         |   |   |   | - |   |   |   | (1,595 | ) |
| Net cash used in investing activities            |   |                                       | -       |   |                          |   | (4,919 | )                                    |   |   | (13,621                   | )      |   |   | - |   |   |   | (18,540 | ) |
|                                             |   |                                       |    |   |                          |   |   |                                 |   |   |                      |   |   |   |   |   |   |   |   |   |
| CASH FLOWS FROM FINANCING ACTIVITIES:            |   |                                       |    |   |                          |   |   |                                 |   |   |                      |   |   |   |   |   |   |
| Proceeds from sale of note hedge claim           |   |                                       | 17,060  |   |                          |   | -      |                                 |   |   | -                         |   |   |   | - |   |   |   | 17,060 |   |
| Non-controlling interest - dividend              |   |                                       | -       |   |                          |   | -      |                                 |   |   | (259                      | )      |   |   | - |   |   |   | (259 | ) |
| Stock options exercised                          |   |                                       | 408     |   |                          |   | -      |                                 |   |   | -                         |   |   |   | - |   |   |   | 408 |   |
| Repurchase of common shares                      |   |                                       | (9,389  | )      |                          |   | -      |                                 |   |   | -                         |   |   |   | - |   |   |   | (9,389 | ) |
| Dividends paid                                   |   |                                       | (26,416 | )      |                          |   | -      |                                 |   |   | -                         |   |   |   | - |   |   |   | (26,416 | ) |
| Excess tax benefit from stock-based payments     |   |                                       | 170     |   |                          |   | -      |                                 |   |   | -                         |   |   |   | - |   |   |   | 170 |   |
| Net cash used in financing activities            |   |                                       | (18,167 | )      |                          |   | -      |                                 |   |   | (259                      | )      |   |   | - |   |   |   | (18,426 | ) |
|                                             |   |                                       |    |   |                          |   |   |                                 |   |   |                      |   |   |   |   |   |   |   |   |   |
| NET CHANGE IN CASH AND CASH EQUIVALENTS          |   |                                       | 60,651  |   |                          |   | 84,021 |                                 |   |   | 235                       |   |   |   | - |   |   |   | 144,907 |   |
| CASH AND CASH EQUIVALENTS, beginning of period   |   |                                       | 13,347  |   |                          |   | 11,027 |                                 |   |   | 11,764                    |   |   |   | - |   |   |   | 36,138 |   |
| CASH AND CASH EQUIVALENTS, end of period         |   | $                                          | 73,998  |   |                          | $      | 95,048 |                                 |   | $      | 11,999                    |   |   | $ | - |   |   | $ | 181,045 |   |

Return to index

----

| Condensed Consolidating Balance Sheets    |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |
|-------------------------------------------|--------|--------------------------------------------|---------|--------|-------------------------------|--------|---------|--------------------------------------|--------|--------|---------------------------|--------|--------|
|                                      |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |   |   |
| (In thousands)                            |   | December 31, 2008                          |    |
|                                      |   | Core Laboratories N.V. (Parent/ Guarantor) |    |   | Core Laboratories LP (Issuer) |   |    | Other Subsidiaries (Non- Guarantors) |   |   | Consolidating Adjustments |   |   | Consolidated Total |   |
| ASSETS                                    |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |   |   |
| CURRENT ASSETS:                           |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |   |   |
| Cash and cash equivalents                 |   | $                                          | 13,347  |   |                          | $      | 11,027  |                                 |   | $      | 11,764                    |   |   | $ | - |   |   | $ | 36,138 |   |
| Accounts receivable, net                  |   |                                       | 232     |   |                          |   | 34,346  |                                 |   |   | 109,715                   |   |   |   | - |   |   |   | 144,293 |   |
| Inventories, net                          |   |                                       | -       |   |                          |   | 3,683   |                                 |   |   | 31,155                    |   |   |   | - |   |   |   | 34,838 |   |
| Prepaid expenses and other current assets |   |                                       | 4,989   |   |                          |   | 6,630   |                                 |   |   | 8,757                     |   |   |   | - |   |   |   | 20,376 |   |
|                                      |   |                                       | 18,568  |   |                          |   | 55,686  |                                 |   |   | 161,391                   |   |   |   | - |   |   |   | 235,645 |   |
|                                      |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |   |   |   |   |   |   |   |
| PROPERTY, PLANT AND EQUIPMENT, net        |   |                                       | -       |   |                          |   | 24,072  |                                 |   |   | 79,391                    |   |   |   | - |   |   |   | 103,463 |   |
| GOODWILL AND INTANGIBLES, net             |   |                                       | 46,986  |   |                          |   | 8,303   |                                 |   |   | 100,303                   |   |   |   | - |   |   |   | 155,592 |   |
| INTERCOMPANY RECEIVABLES                  |   |                                       | 108,491 |   |                          |   | 318,780 |                                 |   |   | 456,421                   |   |   |   | (883,692 | ) |   |   | - |   |
| INVESTMENT IN AFFILIATES                  |   |                                       | 389,500 |   |                          |   | -       |                                 |   |   | 1,147,137                 |   |   |   | (1,536,296 | ) |   |   | 341 |   |
| DEFERRED TAX ASSET                        |   |                                       | 3,283   |   |                          |   | 10,179  |                                 |   |   | 4,246                     |   |   |   | - |   |   |   | 17,708 |   |
| OTHER ASSETS                              |   |                                       | 2,319   |   |                          |   | 5,215   |                                 |   |   | 1,252                     |   |   |   | - |   |   |   | 8,786 |   |
| TOTAL ASSETS                              |   | $                                          | 569,147 |   |                          | $      | 422,235 |                                 |   | $      | 1,950,141                 |   |   | $ | (2,419,988 | ) |   | $ | 521,535 |   |
|                                      |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |   |   |   |   |   |   |   |
| LIABILITIES AND EQUITY                    |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |   |   |   |   |
| CURRENT LIABILITIES:                      |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |   |   |   |   |   |   |   |
| Accounts payable                          |   | $                                          | 626     |   |                          | $      | 8,364   |                                 |   | $      | 32,598                    |   |   | $ | - |   |   | $ | 41,588 |   |
| Other accrued expenses                    |   |                                       | 4,221   |   |                          |   | 20,940  |                                 |   |   | 28,941                    |   |   |   | - |   |   |   | 54,102 |   |
|                                      |   |                                       | 4,847   |   |                          |   | 29,304  |                                 |   |   | 61,539                    |   |   |   | - |   |   |   | 95,690 |   |
|                                      |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |   |   |   |   |   |   |   |
| LONG-TERM DEBT                            |   |                                       | -       |   |                          |   | 194,568 |                                 |   |   | -                         |   |   |   | - |   |   |   | 194,568 |   |
| DEFERRED COMPENSATION                     |   |                                       | 6,118   |   |                          |   | 6,138   |                                 |   |   | 559                       |   |   |   | - |   |   |   | 12,815 |   |
| DEFERRED TAX LIABILITY                    |   |                                       | -       |   |                          |   | -       |                                 |   |   | -                         |   |   |   | - |   |   |   | - |   |
| INTERCOMPANY PAYABLES                     |   |                                       | 356,963 |   |                          |   | 96,351  |                                 |   |   | 430,378                   |   |   |   | (883,692 | ) |   |   | - |   |
| OTHER LONG-TERM LIABILITIES               |   |                                       | 15,092  |   |                          |   | 7,276   |                                 |   |   | 7,809                     |   |   |   | - |   |   |   | 30,177 |   |
|                                      |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |   |   |   |   |   |   |   |
| SHAREHOLDERS' EQUITY                      |   |                                       | 186,127 |   |                          |   | 88,598  |                                 |   |   | 1,447,698                 |   |   |   | (1,536,296 | ) |   |   | 186,127 |   |
| NON-CONTROLLING INTEREST                  |   |                                       | -       |   |                          |   | -       |                                 |   |   | 2,158                     |   |   |   | - |   |   |   | 2,158 |   |
| TOTAL EQUITY                              |   |                                       | 186,127 |   |                          |   | 88,598  |                                 |   |   | 1,449,856                 |   |   |   | (1,536,296 | ) |   |   | 188,285 |   |
|                                      |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |   |   |   |   |   |   |   |
| TOTAL LIABILITIES AND EQUITY         |   | $                                          | 569,147 |   |                          | $      | 422,235 |                                 |   | $      | 1,950,141                 |   |   | $ | (2,419,988 | ) |   | $ | 521,535 |   |

Return to index

----

| Condensed Consolidating Statements of Operations    |   |                                       |    |   |                          |   |    |                                 |   |                            |
|-----------------------------------------------------|--------|--------------------------------------------|---------|--------|-------------------------------|--------|---------|--------------------------------------|--------|---------------------------------|
|                                                |   |                                       |    |   |                          |   |    |                                 |   |                            |   |   |
| (In thousands)                                      |   | Year Ended December 31, 2008               |
|                                                |   | Core Laboratories N.V. (Parent/ Guarantor) |    |   | Core Laboratories LP (Issuer) |   |    | Other Subsidiaries (Non- Guarantors) |   |  Consolidating Adjustments |   |   |  Consolidated Total |
| REVENUES                                            |   |                                       |    |   |                          |   |    |                                 |   |                            |   |   |   |
| Operating revenues                                  |   | $                                          | -       |   |                          | $      | 179,393 |                                 |   | $                               | 601,443 |   |   | $ | - |   |   | $ | 780,836 |   |
| Intercompany revenues                               |   |                                       | 1,569   |   |                          |   | 21,540  |                                 |   |                            | 146,708 |   |   |   | (169,817 | ) |   |   | - |   |
| Earnings from consolidated affiliates               |   |                                       | 121,268 |   |                          |   | -       |                                 |   |                            | 191,812 |   |   |   | (313,080 | ) |   |   | - |   |
| Total revenues                                      |   |                                       | 122,837 |   |                          |   | 200,933 |                                 |   |                            | 939,963 |   |   |   | (482,897 | ) |   |   | 780,836 |   |
|                                                |   |                                       |    |   |                          |   |    |                                 |   |                            |   |   |   |   |   |   |   |   |   |   |
| OPERATING EXPENSES                                  |   |                                       |    |   |                          |   |    |                                 |   |                            |   |   |   |   |   |   |   |   |   |   |
| Operating costs                                     |   |                                       | 1,310   |   |                          |   | 100,793 |                                 |   |                            | 412,679 |   |   |   | - |   |   |   | 514,782 |   |
| General and administrative expenses                 |   |                                       | 11,067  |   |                          |   | 20,518  |                                 |   |                            | 61 |   |   |   | - |   |   |   | 31,646 |   |
| Depreciation and amortization                       |   |                                       | -       |   |                          |   | 5,392   |                                 |   |                            | 16,381 |   |   |   | - |   |   |   | 21,773 |   |
| Other expense (income), net                         |   |                                       | (26,223 | )      |                          |   | (2,341  | )                                    |   |                            | 155,301 |   |   |   | (121,157 | ) |   |   | 5,580 |   |
|                                                |   |                                       |    |   |                          |   |    |                                 |   |                            |   |   |   |   |   |   |   |   |   |   |
| Operating income                                    |   |                                       | 136,683 |   |                          |   | 76,571  |                                 |   |                            | 355,541 |   |   |   | (361,740 | ) |   |   | 207,055 |   |
| Gain on repurchase of senior exchangeable notes     |   |                                       | -       |   |                          |   | 2,829   |                                 |   |                            | - |   |   |   | - |   |   |   | 2,829 |   |
| Interest expense                                    |   |                                       | 1,319   |   |                          |   | 20,239  |                                 |   |                            | 52 |   |   |   | - |   |   |   | 21,610 |   |
|                                                |   |                                       |    |   |                          |   |    |                                 |   |                            |   |   |   |   |   |   |   |   |   |   |
| Income before income tax expense                    |   |                                       | 135,364 |   |                          |   | 59,161  |                                 |   |                            | 355,489 |   |   |   | (361,740 | ) |   |   | 188,274 |   |
| Income tax expense (benefit)                        |   |                                       | 4,198   |   |                          |   | 25,413  |                                 |   |                            | 27,155 |   |   |   | - |   |   |   | 56,766 |   |
|                                                |   |                                       |    |   |                          |   |    |                                 |   |                            |   |   |   |   |   |   |   |   |   |   |
| Net income                                          |   |                                       | 131,166 |   |                          |   | 33,748  |                                 |   |                            | 328,334 |   |   |   | (361,740 | ) |   |   | 131,508 |   |
| Net income attributable to non-controlling interest |   |                                       | -       |   |                          |   | -       |                                 |   |                            | 342 |   |   |   | - |   |   |   | 342 |   |
| Net income attributable to Core Laboratories N.V.   |   | $                                          | 131,166 |   |                          | $      | 33,748  |                                 |   | $                               | 327,992 |   |   | $ | (361,740 | ) |   | $ | 131,166 |   |

| Condensed Consolidating Statements of Cash Flows |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |
|--------------------------------------------------|--------|--------------------------------------------|---------|--------|-------------------------------|--------|---------|--------------------------------------|--------|--------|---------------------------|--------|--------|
|                                             |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |   |   |
| (In thousands)                                   |   | Year Ended December 31, 2008               |    |
|                                             |   | Core Laboratories N.V. (Parent/ Guarantor) |    |   | Core Laboratories LP (Issuer) |   |    | Other Subsidiaries (Non- Guarantors) |   |   | Consolidating Adjustments |   |   | Consolidated Total |   |
|                                             |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |   |   |
| Net cash provided by operating activities        |   | $                                          | 56,840  |   |                          | $      | 66,034  |                                 |   | $      | 32,333                    |   |   | $ | - |   |   | $ | 155,207 |   |
|                                             |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |   | - |   |   |   |   |   |
| CASH FLOWS FROM INVESTING ACTIVITIES:            |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |   |   |   |   |
| Capital expenditures                             |   |                                       | -       |   |                          |   | (10,017 | )                                    |   |   | (20,933                   | )      |   |   | - |   |   |   | (30,950 | ) |
| Patents and other intangibles                    |   |                                       | -       |   |                          |   | (48     | )                                    |   |   | (306                      | )      |   |   | - |   |   |   | (354 | ) |
| Acquisitions, net of cash acquired               |   |                                       | -       |   |                          |   | -       |                                 |   |   | (11,536                   | )      |   |   | - |   |   |   | (11,536 | ) |
| Non-controlling interest contribution            |   |                                       | -       |   |                          |   | -       |                                 |   |   | 370                       |   |   |   | - |   |   |   | 370 |   |
| Proceeds from sale of assets                     |   |                                       | -       |   |                          |   | 2,698   |                                 |   |   | 1,100                     |   |   |   | - |   |   |   | 3,798 |   |
| Premiums on life insurance                       |   |                                       | -       |   |                          |   | (2,436  | )                                    |   |   | -                         |   |   |   | - |   |   |   | (2,436 | ) |
| Net cash used in investing activities            |   |                                       | -       |   |                          |   | (9,803  | )                                    |   |   | (31,305                   | )      |   |   | - |   |   |   | (41,108 | ) |
|                                             |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |   |   |   |   |   |   |   |
| CASH FLOWS FROM FINANCING ACTIVITIES:            |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |   |   |   |   |
| Repayment of debt borrowings                     |   |                                       | (3,024  | )      |                          |   | (58,022 | )                                    |   |   | -                         |   |   |   | - |   |   |   | (61,046 | ) |
| Proceeds from debt borrowings                    |   |                                       | -       |   |                          |   | 5,000   |                                 |   |   | -                         |   |   |   | - |   |   |   | 5,000 |   |
| Capital lease obligations                        |   |                                       | -       |   |                          |   | -       |                                 |   |   | (351                      | )      |   |   | - |   |   |   | (351 | ) |
| Stock options exercised                          |   |                                       | 1,167   |   |                          |   | -       |                                 |   |   | -                         |   |   |   | - |   |   |   | 1,167 |   |
| Repurchase of common shares                      |   |                                       | (31,740 | )      |                          |   | -       |                                 |   |   | -                         |   |   |   | - |   |   |   | (31,740 | ) |
| Dividends paid                                   |   |                                       | (27,645 | )      |                          |   | -       |                                 |   |   | -                         |   |   |   | - |   |   |   | (27,645 | ) |
| Excess tax benefit from stock-based payments     |   |                                       | 11,037  |   |                          |   | -       |                                 |   |   | -                         |   |   |   | - |   |   |   | 11,037 |   |
| Net cash used in financing activities            |   |                                       | (50,205 | )      |                          |   | (53,022 | )                                    |   |   | (351                      | )      |   |   | - |   |   |   | (103,578 | ) |
|                                             |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |   |   |   |   |   |   |   |
| NET CHANGE IN CASH AND CASH EQUIVALENTS          |   |                                       | 6,635   |   |                          |   | 3,209   |                                 |   |   | 677                       |   |   |   | - |   |   |   | 10,521 |   |
| CASH AND CASH EQUIVALENTS, beginning of period   |   |                                       | 6,712   |   |                          |   | 7,818   |                                 |   |   | 11,087                    |   |   |   | - |   |   |   | 25,617 |   |
| CASH AND CASH EQUIVALENTS, end of period         |   | $                                          | 13,347  |   |                          | $      | 11,027  |                                 |   | $      | 11,764                    |   |   | $ | - |   |   | $ | 36,138 |   |

Return to index

----

| Condensed Consolidating Statements of Operations    |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |
|-----------------------------------------------------|--------|--------------------------------------------|---------|--------|-------------------------------|--------|---------|--------------------------------------|--------|--------|---------------------------|--------|--------|
|                                                |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |   |   |
| (In thousands)                                      |   | Year Ended December 31, 2007               |    |
|                                                |   | Core Laboratories N.V. (Parent/ Guarantor) |    |   | Core Laboratories LP (Issuer) |   |    | Other Subsidiaries (Non- Guarantors) |   |   | Consolidating Adjustments |   |   | Consolidated Total |   |
| REVENUES                                            |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |   |   |
| Operating revenues                                  |   | $                                          | -       |   |                          | $      | 136,719 |                                 |   | $      | 533,821                   |   |   | $ | - |   |   | $ | 670,540 |   |
| Intercompany revenues                               |   |                                       | 1,281   |   |                          |   | 18,215  |                                 |   |   | 128,159                   |   |   |   | (147,655 | ) |   |   | - |   |
| Earnings from consolidated affiliates               |   |                                       | 109,725 |   |                          |   | -       |                                 |   |   | 192,546                   |   |   |   | (302,271 | ) |   |   | - |   |
| Total revenues                                      |   |                                       | 111,006 |   |                          |   | 154,934 |                                 |   |   | 854,526                   |   |   |   | (449,926 | ) |   |   | 670,540 |   |
|                                                |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |   |   |   |   |   |   |   |
| OPERATING EXPENSES                                  |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |   |   |   |   |   |   |   |
| Operating costs                                     |   |                                       | 1,146   |   |                          |   | 80,638  |                                 |   |   | 367,407                   |   |   |   | - |   |   |   | 449,191 |   |
| General and administrative expenses                 |   |                                       | 8,576   |   |                          |   | 25,225  |                                 |   |   | 36                        |   |   |   | - |   |   |   | 33,837 |   |
| Depreciation and amortization                       |   |                                       | -       |   |                          |   | 5,504   |                                 |   |   | 13,972                    |   |   |   | - |   |   |   | 19,476 |   |
| Other expense (income), net                         |   |                                       | (17,297 | )      |                          |   | (8,921  | )                                    |   |   | 113,851                   |   |   |   | (103,548 | ) |   |   | (15,915 | ) |
|                                                |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |   |   |   |   |   |   |   |
| Operating income                                    |   |                                       | 118,581 |   |                          |   | 52,488  |                                 |   |   | 359,260                   |   |   |   | (346,378 | ) |   |   | 183,951 |   |
| Interest expense                                    |   |                                       | 115     |   |                          |   | 18,225  |                                 |   |   | 39                        |   |   |   | - |   |   |   | 18,379 |   |
|                                                |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |   |   |   |   |   |   |   |
| Income before income tax expense                    |   |                                       | 118,466 |   |                          |   | 34,263  |                                 |   |   | 359,221                   |   |   |   | (346,378 | ) |   |   | 165,572 |   |
| Income tax expense (benefit)                        |   |                                       | 7,254   |   |                          |   | 22,729  |                                 |   |   | 24,274                    |   |   |   | - |   |   |   | 54,257 |   |
|                                                |   |                                       |    |   |                          |   |    |                                 |   |   |                      |   |   |   |   |   |   |   |   |   |
| Net income                                          |   |                                       | 111,212 |   |                          |   | 11,534  |                                 |   |   | 334,947                   |   |   |   | (346,378 | ) |   |   | 111,315 |   |
| Net income attributable to non-controlling interest |   |                                       | -       |   |                          |   | -       |                                 |   |   | 103                       |   |   |   | - |   |   |   | 103 |   |
| Net income attributable to Core Laboratories N.V.   |   | $                                          | 111,212 |   |                          | $      | 11,534  |                                 |   | $      | 334,844                   |   |   | $ | (346,378 | ) |   | $ | 111,212 |   |

| Condensed Consolidating Statements of Cash Flows |   |                                       |     |   |                          |   |    |                                 |   |   |                      |   |   |
|--------------------------------------------------|--------|--------------------------------------------|----------|--------|-------------------------------|--------|---------|--------------------------------------|--------|--------|---------------------------|--------|--------|
|                                             |   |                                       |     |   |                          |   |    |                                 |   |   |                      |   |   |   |   |
| (In thousands)                                   |   | Year Ended December 31, 2007               |     |
|                                             |   | Core Laboratories N.V. (Parent/ Guarantor) |     |   | Core Laboratories LP (Issuer) |   |    | Other Subsidiaries (Non- Guarantors) |   |   | Consolidating Adjustments |   |   | Consolidated Total |   |
|                                             |   |                                       |     |   |                          |   |    |                                 |   |   |                      |   |   |   |   |
| Net cash provided by operating activities        |   | $                                          | 139,192  |   |                          | $      | (13,245 | )                                    |   | $      | (252                      | )      |   | $ | - |   |   | $ | 125,695 |   |
|                                             |   |                                       |     |   |                          |   |    |                                 |   |   |                      |   |   |   | - |   |   |   |   |   |
| CASH FLOWS FROM INVESTING ACTIVITIES:            |   |                                       |     |   |                          |   |    |                                 |   |   |                      |   |   |   |   |   |   |
| Capital expenditures                             |   |                                       | -        |   |                          |   | (4,428  | )                                    |   |   | (19,399                   | )      |   |   | - |   |   |   | (23,827 | ) |
| Patents and other intangibles                    |   |                                       | -        |   |                          |   | (69     | )                                    |   |   | (248                      | )      |   |   | - |   |   |   | (317 | ) |
| Acquisitions, net of cash acquired               |   |                                       | -        |   |                          |   | (7,338  | )                                    |   |   | -                         |   |   |   | - |   |   |   | (7,338 | ) |
| Proceeds from sale of assets                     |   |                                       | -        |   |                          |   | 62      |                                 |   |   | 13,727                    |   |   |   | - |   |   |   | 13,789 |   |
| Premiums on life insurance                       |   |                                       | -        |   |                          |   | (2,282  | )                                    |   |   | -                         |   |   |   | - |   |   |   | (2,282 | ) |
| Net cash used in investing activities            |   |                                       | -        |   |                          |   | (14,055 | )                                    |   |   | (5,920                    | )      |   |   | - |   |   |   | (19,975 | ) |
|                                             |   |                                       |     |   |                          |   |    |                                 |   |   |                      |   |   |   |   |   |   |   |   |   |
| CASH FLOWS FROM FINANCING ACTIVITIES:            |   |                                       |     |   |                          |   |    |                                 |   |   |                      |   |   |   |   |   |   |
| Repayment of debt borrowings                     |   |                                       | (4,146   | )      |                          |   | (100    | )                                    |   |   | -                         |   |   |   | - |   |   |   | (4,246 | ) |
| Proceeds from debt borrowings                    |   |                                       | 4,516    |   |                          |   | -       |                                 |   |   | -                         |   |   |   | - |   |   |   | 4,516 |   |
| Capital lease obligations                        |   |                                       | -        |   |                          |   | -       |                                 |   |   | (7                        | )      |   |   | - |   |   |   | (7 | ) |
| Stock options exercised                          |   |                                       | 18,454   |   |                          |   | -       |                                 |   |   | -                         |   |   |   | - |   |   |   | 18,454 |   |
| Repurchase of common shares                      |   |                                       | (181,812 | )      |                          |   | -       |                                 |   |   | -                         |   |   |   | - |   |   |   | (181,812 | ) |
| Debt refinancing costs                           |   |                                       | -        |   |                          |   | (167    | )                                    |   |   | -                         |   |   |   | - |   |   |   | (167 | ) |
| Excess tax benefit from stock-based payments     |   |                                       | 28,936   |   |                          |   | -       |                                 |   |   | -                         |   |   |   | - |   |   |   | 28,936 |   |
| Net cash used in financing activities            |   |                                       | (134,052 | )      |                          |   | (267    | )                                    |   |   | (7                        | )      |   |   | - |   |   |   | (134,326 | ) |
|                                             |   |                                       |     |   |                          |   |    |                                 |   |   |                      |   |   |   |   |   |   |   |   |   |
| NET CHANGE IN CASH AND CASH EQUIVALENTS          |   |                                       | 5,140    |   |                          |   | (27,567 | )                                    |   |   | (6,179                    | )      |   |   | - |   |   |   | (28,606 | ) |
| CASH AND CASH EQUIVALENTS, beginning of period   |   |                                       | 1,572    |   |                          |   | 35,385  |                                 |   |   | 17,266                    |   |   |   | - |   |   |   | 54,223 |   |
| CASH AND CASH EQUIVALENTS, end of period         |   | $                                          | 6,712    |   |                          | $      | 7,818   |                                 |   | $      | 11,087                    |   |   | $ | - |   |   | $ | 25,617 |   |

Return to index

----

|   | 17. RECENT ACCOUNTING PRONOUNCEMENTS |
|--------|--------------------------------------|

Return to index

----

|   | 18. UNAUDITED SELECTED QUARTERLY RESULTS OF OPERATIONS |
|--------|--------------------------------------------------------|

| Quarter ended 2009                                                          |   | December 31 |          |   | September 30 |   |    | June 30 |   |   | March 31 |   |
|-----------------------------------------------------------------------------|--------|-------------|---------------|--------|--------------|--------|---------|---------|--------|--------|----------|--------|
|                                                                        |   |        |          |   |         |   |    |    |   |   |     |   |
| Services and product sales revenues                                         |   | $           |  181,599 |   |         | $      | 167,802 |    |   | $      | 167,262  |   |   | $ | 178,876 |   |
| Cost of services and product sales                                          |   |        | 120,565       |   |         |   | 112,175 |    |   |   | 108,997  |   |   |   | 116,032 |   |
| Other operating expenses                                                    |   |        | 16,758        |   |         |   | 11,428  |    |   |   | 6,577    |   |   |   | 16,225 |   |
| Operating income                                                            |   |        | 44,276        |   |         |   | 44,199  |    |   |   | 51,688   |   |   |   | 46,619 |   |
| Interest expense                                                            |   |        | 3,988         |   |         |   | 3,895   |    |   |   | 3,840    |   |   |   | 3,800 |   |
| Income before income tax expense                                            |   |        | 40,288        |   |         |   | 40,304  |    |   |   | 47,848   |   |   |   | 42,819 |   |
| Income tax expense                                                          |   |        | 16,511        |   |         |   | 9,189   |    |   |   | 17,884   |   |   |   | 13,580 |   |
| Net income                                                                  |   |        | 23,777        |   |         |   | 31,115  |    |   |   | 29,964   |   |   |   | 29,239 |   |
|     Net income attributable to non-controlling interest |   |        | 160           |   |         |   | 127     |    |   |   | 157      |   |   |   | 47 |   |
| Net income attributable to Core Laboratories N.V.                           |   | $           | 23,617        |   |         | $      | 30,988  |    |   | $      | 29,807   |   |   | $ | 29,192 |   |
|                                                                        |   |        |          |   |         |   |    |    |   |   |     |   |   |   |   |   |
| Per share information:                                                      |   |        |          |   |         |   |    |    |   |   |     |   |   |   |   |   |
| Basic earnings per share                                                    |   | $           | 1.03          |   |         | $      | 1.35    |    |   | $      | 1.30     |   |   | $ | 1.27 |   |
| Diluted earnings per share (1)                                              |   | $           | 1.00          |   |         | $      | 1.33    |    |   | $      | 1.29     |   |   | $ | 1.26 |   |
|                                                                        |   |        |          |   |         |   |    |    |   |   |     |   |   |   |   |   |
| Weighted average common shares outstanding:                                 |   |        |          |   |         |   |    |    |   |   |     |   |   |   |   |   |
| Basic                                                                       |   |        | 22,983        |   |         |   | 22,969  |    |   |   | 22,955   |   |   |   | 22,970 |   |
| Diluted                                                                     |   |        | 23,677        |   |         |   | 23,250  |    |   |   | 23,179   |   |   |   | 23,210 |   |

| Quarter ended 2008                                                          |   | December 31 |          |   | September 30 |   |    | June 30 |   |   | March 31 |   |
|-----------------------------------------------------------------------------|--------|-------------|---------------|--------|--------------|--------|---------|---------|--------|--------|----------|--------|
|                                                                        |   |        |          |   |         |   |    |    |   |   |     |   |
| Services and product sales revenues                                         |   | $           |  201,188 |   |         | $      | 202,523 |    |   | $      | 197,688  |   |   | $ | 179,437 |   |
| Cost of services and product sales                                          |   |        | 130,194       |   |         |   | 134,205 |    |   |   | 130,910  |   |   |   | 119,473 |   |
| Other operating expenses                                                    |   |        | 18,579        |   |         |   | 13,145  |    |   |   | 11,682   |   |   |   | 15,593 |   |
| Operating income                                                            |   |        | 52,415        |   |         |   | 55,173  |    |   |   | 55,096   |   |   |   | 44,371 |   |
| Gain on repurchase of senior exchangeable notes                             |   |        | 2,829         |   |         |   | -       |    |   |   | -        |   |   |   | - |   |
| Interest expense                                                            |   |        | 4,235         |   |         |   | 4,593   |    |   |   | 8,000    |   |   |   | 4,782 |   |
| Income before income tax expense                                            |   |        | 51,009        |   |         |   | 50,580  |    |   |   | 47,096   |   |   |   | 39,589 |   |
| Income tax expense                                                          |   |        | 15,732        |   |         |   | 13,643  |    |   |   | 14,652   |   |   |   | 12,739 |   |
| Net income                                                                  |   |        | 35,277        |   |         |   | 36,937  |    |   |   | 32,444   |   |   |   | 26,850 |   |
|     Net income attributable to non-controlling interest |   |        | 59            |   |         |   | 103     |    |   |   | 77       |   |   |   | 103 |   |
| Net income attributable to Core Laboratories N.V.                           |   | $           | 35,218        |   |         | $      | 36,834  |    |   | $      | 32,367   |   |   | $ | 26,747 |   |
|                                                                        |   |        |          |   |         |   |    |    |   |   |     |   |   |   |   |   |
| Per share information:                                                      |   |        |          |   |         |   |    |    |   |   |     |   |   |   |   |   |
| Basic earnings per share                                                    |   | $           | 1.53          |   |         | $      | 1.60    |    |   | $      | 1.41     |   |   | $ | 1.16 |   |
| Diluted earnings per share (1)                                              |   | $           | 1.51          |   |         | $      | 1.53    |    |   | $      | 1.32     |   |   | $ | 1.11 |   |
|                                                                        |   |        |          |   |         |   |    |    |   |   |     |   |   |   |   |   |
| Weighted average common shares outstanding:                                 |   |        |          |   |         |   |    |    |   |   |     |   |   |   |   |   |
| Basic                                                                       |   |        | 23,022        |   |         |   | 23,034  |    |   |   | 22,995   |   |   |   | 22,982 |   |
| Diluted                                                                     |   |        | 23,289        |   |         |   | 24,082  |    |   |   | 24,452   |   |   |   | 23,998 |   |

|   | (1) | The sum of the individual quarterly diluted earnings per share amounts may not agree with the year-to-date diluted earnings per share amounts as each quarterly computation is based on the weighted average number of diluted common shares outstanding during that period. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Return to index

----

Schedule II - Valuation and Qualifying Account

|                         |                                                                |   |       |   |   | Additions      |   |   |       |   |   |      |   |   |       |   |
|------------------------------|---------------------------------------------------------------------|--------|------------|--------|--------|----------------|--------|--------|------------|--------|--------|-----------|--------|--------|------------|--------|
|                         |                                                                |   | Balance at |   |   | Charged to/    |   |   |       |   |   |      |   |   | Balance at |   |
|                         |                                                                |   | Beginning  |   |   | Recovered from |   |   |       |   |   |      |   |   | End of     |   |
|                         |                                                                |   | of Period  |   |   | Expense        |   |   | Write-offs |   |   | Other (1) |   |   | Period     |   |
| Year ended December 31, 2009 |                                                                |   |       |   |   |           |   |   |       |   |   |      |   |   |       |
|                         | Reserve for doubtful accounts                                       |   | $          | 3,535  |   |           | $      | 545    |       |   | $      | (943      | )      |   | $          | 65     |   |   | $ | 3,202 |   |
|                         |                                                                |   |       |   |   |           |   |   |       |   |   |      |   |   |       |   |   |   |   |   |
| Year ended December 31, 2008 |                                                                |   |       |   |   |           |   |   |       |   |   |      |   |   |       |   |   |   |   |   |
|                         | Reserve for doubtful accounts                                       |   | $          | 4,199  |   |           | $      | (233   | )          |   | $      | (510      | )      |   | $          | 79     |   |   | $ | 3,535 |   |
|                         |                                                                |   |       |   |   |           |   |   |       |   |   |      |   |   |       |   |   |   |   |   |   |
| Year ended December 31, 2007 |                                                                |   |       |   |   |           |   |   |       |   |   |      |   |   |       |   |   |   |   |   |
|                         | Reserve for doubtful accounts                                       |   | $          | 4,340  |   |           | $      | 262    |       |   | $      | (629      | )      |   | $          | 226    |   |   | $ | 4,199 |   |
|                         |                                                                |   |       |   |   |           |   |   |       |   |   |      |   |   |       |   |   |   |   |   |   |
| (1)                          | Comprised primarily of differences due to changes in exchange rate. |   |

Return to index

----

| Name                                                         |   | Legal Seat                         |   | Ownership % |
|--------------------------------------------------------------|--------|------------------------------------|--------|-------------|
| Core Laboratories Resources N.V.                             |   | Curacao, Netherlands Antilles      |   | 100%        |
| Core Laboratories International Licensing N.V.               |   | Curacao, Netherlands Antilles      |   | 100%        |
| Core Laboratories International Trading N.V.                 |   | Curacao, Netherlands Antilles      |   | 100%        |
| Core Laboratories I.P. Inc.                                  |   | Delaware, United States            |   | 100%        |
| Core Laboratories Holding Inc.                               |   | Delaware, United States            |   | 100%        |
| Core Laboratories Middle East Services B.V.                  |   | Rotterdam, The Netherlands         |   | 100%        |
| Core Laboratories LP                                         |   | Delaware, United States            |   | 100%        |
| Core Laboratories Canada Limited                             |   | Alberta, Canada                    |   | 100%        |
| PT Corelab Indonesia                                         |   | Jakarta, Indonesia                 |   | 70%         |
| Core Laboratories Malaysia SDN BHD                           |   | Kuala Lumpur, Malaysia             |   | 100%        |
| Core Laboratories Australia PTY LTD                          |   | Perth, Australia                   |   | 100%        |
| Core Laboratories International B.V.                         |   | Amsterdam, The Netherlands         |   | 100%        |
| Core Laboratories Sales N.V.                                 |   | Curacao, Netherlands Antilles      |   | 100%        |
| Core Laboratories (U.K.) Limited                             |   | London, United Kingdom             |   | 100%        |
| Core Laboratories Coöperatief U.A.                      |   | Amsterdam, The Netherlands         |   | 100%        |
| Corelab Nigeria Limited                                      |   | Lagos, Nigeria                     |   | 100%        |
| Core Laboratories Venezuela S.A.                             |   | Caracas, Venezuela                 |   | 100%        |
| Core Laboratories Corporate Holding B.V.                     |   | Amsterdam, The Netherlands         |   | 100%        |
| Corelab Brasil Ltda                                          |   | Rio de Janeiro, Brazil             |   | 100%        |
| Abdullah Fuad Core Laboratory Company                        |   | Dammam, Saudi Arabia               |   | 51%         |
| Core Laboratories Holdings LLC                               |   | Delaware, United States            |   | 100%        |
| Core Laboratories LLC                                        |   | Delaware, United States            |   | 100%        |
| Saybolt International B.V.                                   |   | Rotterdam, The Netherlands         |   | 100%        |
| Saybolt Holding B.V.                                         |   | Rotterdam, The Netherlands         |   | 100%        |
| Saybolt Denmark A/S                                          |   | Copenhagen, Denmark                |   | 100%        |
| Saybolt van Duyn GmbH                                        |   | Essen, Germany                     |   | 100%        |
| Saybolt Espana S.A.                                          |   | Madrid, Spain                      |   | 100%        |
| Saybolt Estonia Ltd.                                         |   | Tallinn, Estonia                   |   | 100%        |
| Saybolt Finland Oy                                           |   | Hamina, Finland                    |   | 100%        |
| Saybolt Italia S.R.L.                                        |   | Siracusa, Italy                    |   | 100%        |
| Saybolt Malta Ltd.                                           |   | Kalafran, Malta                    |   | 100%        |
| Saybolt Greece, Ltd.                                         |   | Athens, Greece                     |   | 100%        |
| Saybolt (Portugal) Inspeccao de Productos Petroliferos, Lda. |   | Lisbon, Portugal                   |   | 100%        |
| Saybolt South Africa PTY LTD                                 |   | Cape Town, South Africa            |   | 73%         |
| Saybolt Sweden AB                                            |   | Gothenburg, Sweden                 |   | 100%        |
| Saybolt United Kingdom Ltd.                                  |   | Purfleet, United Kingdom           |   | 100%        |
| Saybolt North America B.V.                                   |   | Rotterdam, The Netherlands         |   | 100%        |
| Saybolt de Mexico S.A. de C.V.                               |   | Coatzacoalcos, Mexico              |   | 100%        |
| Saybolt LP                                                   |   | Delaware, United States            |   | 100%        |
| Core Laboratories Panama, S.A.                               |   | Panama City, Panama                |   | 100%        |
| E.W. Saybolt & Co. (Cayman) Ltd.                         |   | Georgetown, Grand Cayman           |   | 100%        |
| Saybolt Analyt Holding B.V.                                  |   | Rotterdam, The Netherlands         |   | 100%        |
| ZAO Saybolt Eurasia                                          |   | Moscow, Russian Federation         |   | 100%        |
| Saybolt−Ukraine                                        |   | Odessa, Ukraine                    |   | 100%        |
| Saybolt Bulgaria Ltd.                                        |   | Bourgas, Bulgaria                  |   | 100%        |
| UAB Saybolt-Baltija, Ltd.                                    |   | Klaipeda, Lithuania                |   | 100%        |
| Saybolt Latvia                                               |   | Ventspils, Latvia                  |   | 100%        |
| Saybolt St. Eustatius                                        |   | St. Eustatius, Netherland Antilles |   | 100%        |
| Saybolt Bahamas Ltd.                                         |   | Freeport, Bahamas                  |   | 100%        |
| Saybolt de Costa Rica, S.A.                                  |   | San Jose, Costa Rica               |   | 99%         |
| Saybolt de Colombia Ltda.                                    |   | Barranquilla, Colombia             |   | 95%         |
| Saybolt Aruba N.V.                                           |   | San Nicolas, Aruba                 |   | 100%        |
| Saybolt Bonaire N.V.                                         |   | Bonaire, Netherlands Antilles      |   | 100%        |
| Saybolt Caribbean N.V.                                       |   | San Nicolas, Aruba                 |   | 100%        |

Return to index

----

| Name                                                                 |   | Legal Seat                        |   | Ownership % |
|----------------------------------------------------------------------|--------|-----------------------------------|--------|-------------|
| Saybolt Curacao N.V.                                                 |   | Curacao, Netherlands Antilles     |   | 100%        |
| Saybolt Trinidad & Tobago Ltd.                                   |   | Marabella, Trinidad               |   | 100%        |
| Saybolt Eastern Hemisphere B.V.                                      |   | Rotterdam, The Netherlands        |   | 100%        |
| Saybolt Malaysia SDN BHD                                             |   | Kuala Lumpur, Malaysia            |   | 49%         |
| PT Citra Wosaji Indonesia                                            |   | Jakarta, Indonesia                |   | 65%         |
| Saybolt Azerbaijan                                                   |   | Baku, Azerbaijan                  |   | 100%        |
| Saybolt Azerbaijan B.V.                                              |   | Rotterdam, The Netherlands        |   | 50%         |
| Beheersmaatschappij Het Scheur BV                                    |   | Rotterdam, The Netherlands        |   | 100%        |
| Core Laboratories El Salvador S.A. de C.V.                           |   | San Salvador, El Salvador         |   | 100%        |
| Saybolt Belgium N.V.                                                 |   | Antwerp, Belgium                  |   | 100%        |
| Saybolt (Tianjin) Meteorology & Inspection Company Ltd.          |   | Tianjin, China                    |   | 100%        |
| Core Lab Science and Technology (Beijing) Co Ltd.                    |   | Beijing, China                    |   | 100%        |
| Saybolt Latin America B.V.                                           |   | Rotterdam, The Netherlands        |   | 100%        |
| Core Laboratories Angola Ltd.                                        |   | Luanda, Angola                    |   | 100%        |
| Saybolt Inspection Services India Private Limited                    |   | Mumbai, India                     |   | 100%        |
| Saybolt Inspection Services Kazakhstan LLP                           |   | Aktau,  Kazakhstan      |   | 100%        |
| Saybolt (Singapore) PTE LTD                                          |   | Singapore, Singapore              |   | 100%        |
| Core Laboratories (H.K.) Limited                                     |   | Hong Kong, China                  |   | 100%        |
| Quantoil Ltd.                                                        |   | London, United Kingdom            |   | 100%        |
| E.W. Saybolt & Co. S.A.                                          |   | Panama City, Panama               |   | 100%        |
| Saybolt Surveillance and Laboratory Services Joint Stock Corporation |   | Istanbul, Turkey                  |   | 100%        |
| Saybolt Inspection Romania S.R.L.                                    |   | Constanta, Romania                |   | 100%        |
| Owen Oil Tools LP                                                    |   | Delaware, United States           |   | 100%        |
| Owen Oil Tools de Mexico, S.A. de C.V.                               |   | Tabasco, Mexico                   |   | 100%        |
| Owen Compliance Services, Inc.                                       |   | Texas, United States              |   | 100%        |
| Owen de Mexico S.A. de C.V.                                          |   | Mexico City, Mexico               |   | 100%        |
| Owen Oil Tools (U.K.) Ltd.                                           |   | Croydon, United Kingdom           |   | 100%        |
| Owen Oil Tools de Argentina, S.A.                                    |   | Buenos Aires, Argentina           |   | 100%        |
| Core Laboratories LLP (Kazakhstan)                                   |   | Aktau, Kazakhstan                 |   | 100%        |
| ZAO Petroleum Analysts                                               |   | Moscow, Russian Federation        |   | 100%        |
| ZAO Lab Technics                                                     |   | Moscow, Russian Federation        |   | 100%        |
| Saybolt Test OOO                                                     |   | Bashkortostan, Russian Federation |   | 100%        |
| Saybolt Armenia                                                      |   | Yerevan, Armenia                  |   | 100%        |
| Core Lab de Mexico, S.A. de C.V.                                     |   | Mexico City, Mexico               |   | 100%        |
| Core Lab Operations S.A. de C.V.                                     |   | Mexico City, Mexico               |   | 100%        |
| Colab Newco S.A. de C.V.                                             |   | Mexico City, Mexico               |   | 100%        |
| ProTechnics de Mexico, S.A. de C.V.                                  |   | Mexico City, Mexico               |   | 100%        |
| Core Lab Services S.A. de C.V.                                       |   | Mexico City, Mexico               |   | 100%        |
| Stim-Lab, Inc.                                                       |   | Oklahoma, United States           |   | 100%        |
| Core Laboratories Global N.V.                                        |   | Curacao, Netherlands Antilles     |   | 100%        |
| CTC Pulsonic Nigeria Limited                                         |   | Lagos, Nigeria                    |   | 80%         |
| Production Enhancement Corporation                                   |   | Delaware, United States           |   | 100%        |
| PENCOR International Ltd.                                            |   | Jersey, Channel Islands           |   | 100%        |
| Coreton Limited                                                      |   | Croydon, United Kingdom           |   | 100%        |
| Labton Limited                                                       |   | London,  United Kingdom |   | 100%        |
| FE & FEFH Holding, Inc.                                          |   | Alberta, Canada                   |   | 100%        |
| Saybolt Tunisie SarL                                                 |   | Tunis, Tunisia                    |   | 49%         |
| Saybolt Med S.A.                                                     |   | Tunis, Tunisia                    |   | 49%         |
| Saybolt Saudi Arabia Co., Ltd.                                       |   | Jubail, Saudi Arabia              |   | 45%         |
| Core Laboratories Malta Holding Limited                              |   | Valletta, Malta                   |   | 99%         |
| Core Laboratories Malta Limited                                      |   | Valletta, Malta                   |   | 99%         |
| Saybolt Maroc                                                        |   | Mohammedia, Morocco               |   | 49%         |
| Shanghai SIC - Saybolt Commodities Surveying Co Ltd.                 |   | Beijing, China                    |   | 50%         |

Return to index

----

Return to index

----